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Abstract 
Antibiotic resistance is quickly becoming one of the biggest modern-day threats to human 
health. It has not only been observed in the clinic but in natural environments as well. 
Selection for antimicrobial resistant bacteria in the marine environment has been shown to 
be driven factors such as low concentrations of antibiotics entering the environment through 
discharge from wastewater treatment plants and run off from agricultural sites. However, 
antimicrobial resistance is likely to not be solely due to anthropogenic pollution, as it is an 
ancient mechanism and has been found in environments with minimal human exposure. 
Here we investigated whether natural antimicrobial producers, i.e. seaweeds, select for 
antibiotic resistant bacteria.  
We used both culture-based and molecular techniques to characterise the bacterial 
communities associated with different seaweed species, focusing on the human pathogens 
Vibrio, E. coli and S. aureus. Vibrio was harboured by all the seaweeds tested but E. coli 
and S. aureus were not. For the first time, we tested if Vibrio isolated from seaweed are 
locally adapted to their host macroalgae using a novel seaweed media assay. Our results 
showed Vibrio did not display local adaption. We tested the resistance profiles of bacteria 
isolated from seaweeds and found Vibrio showed cross-resistance to antibiotics and natural 
antimicrobial, in the form of methanolic seaweed extracts. We can conclude seaweeds 
harbour antibiotic resistant bacteria, but specific species of seaweeds do not select for 
specific antibiotic resistance.  
We quantified the prevalence of a biomarker for antibiotic resistance, the intI1 gene, and 
found seaweed select for antibiotic resistant bacteria independent of anthropogenic 
pollution, suggesting seaweed-associated bacterial resistance is an intrinsic mechanism.  
Using metagenomics, we characterised possible antimicrobial resistance genes associated 
with different seaweed species from which we were able identify eflamycin, aminocoumarin 
and fluoroquinolone resistance genes on all the seaweeds tested. Two of the antibiotic 
classes are produced by Streptomyces, which is present on seaweeds. Suggesting 
resistance on seaweeds is selected for by bacterial community or the genes characterised 
show cross-resistance to seaweed antimicrobials. 
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Chapter 1: General Introduction 
1.1 Brief History of Antibiotics  
The ‘antibiotic era’ is thought to have started at the beginning of the 20th century with Paul 
Ehrlich’s search for the ‘magic bullet’ for which he argued that “chemical compounds could 
be synthesized to exert their full action exclusively on the parasite harboured within the 
organisms” (1). In 1904, this idea led to Ehrlich developing a large-scale screening 
programme to find a drug to treat syphilis, which is caused by the bacteria Treponema 
pallidium. It took five years of testing derivatives of arsenic to discover a compound, 
arsphenamine, which could be used to treat syphilis (2). It first showed promise in infected 
rabbits and treated patients with venereal disease (3). The drug was a derivative of the 
highly toxic drug atoxyl and was marketed by Hoechst under the name salvarsan, however 
it was insoluble in water making it hard to administer and had toxic and painful side effects 
(2). In 1912 salvarsan was replaced with the less toxic more soluble drug neosalvarsan, 
which is today classed as a prodrug and used for chemotherapy (4). 
Ehrlich’s systematic screening programme has since helped in the discovery of thousands 
of drugs, including the class of drugs we know to today as the sulphonamides. In 1932 the 
first sulpha drug, Prontosil, was synthesised by a group of Bayer researchers testing dye 
derivatives for antimicrobial properties (5). However, the active compound sulphanilamide 
had been used in the dye industry for many years therefore could not be patented. Many 
companies started producing their own derivatives of the drug leading to a ‘sulpha craze’. 
Unfortunately, this craze lead to the elixir sulphanilamide disaster in 1937 from which 100 
people died, sparking the Federal food, drug and cosmetic act in 1938 (6). Despite the 
disaster, sulphonamides were widely used throughout World War II but due to high instances 
of resistance the use of sulpha drugs was reduced by 97% in the 1990’s. The prevalence of 
sulphonamide resistant Escherichia coli in the clinic is still 40%-45% (7). 
In the late 1940’s penicillin took over as the most frequently prescribed drug and it is still 
one of the most well-known antimicrobial agents. It was initially isolated from Penicillium 
notatum mould by Alexander Fleming in 1928 (8). It was not until 1945 that penicillin could 
be mass produced as it took over 12 years from discovery for a purification method to give 
a sufficient yield to undergo clinical trials (9).  Initially, penicillin could only treat a narrow 
range of infections therefore new derivatives of the drug were needed which sparked the 
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synthesis of ampicillin in 1961, which had better bioavailability and a broader spectrum (10). 
Penicillin and it derivatives are part of the β-lactam group of antibiotics, other examples of 
β-lactam antibiotics include carbapenems, cephalosporins and monobactams (11).  
The approaches used to discover and develop Salvarson, Prontosil and penicillin led to the 
discovery of over 20 novel classes of antibiotics between 1950 and 1970 (2). Since that time 
no new classes have been found and only variations on existing compounds have been 
approved (12). The main reasons no new antibiotic classes have been discovered is 
because there is a limited number of metabolic pathways which can be targeted (13) and 
the huge costs involved in getting a drug to market (14). A lack of new antibiotics is becoming 
a massive problem due to the emerging issue of resistance to the drugs currently used to 
treat bacterial infections (15-17).  
1.2 The Antimicrobial Resistance Epidemic 
In 2014 the UK government commissioned a review on antimicrobial resistance conducted 
by Sir Jim O’Neill which estimated that antimicrobial resistance could be the cause of 10 
million deaths per year by 2050, overtaking cancer as the leading cause of death, and 
potentially costing the world $100 trillion (15). In the same year the World Health 
Organisation (WHO) released a statement saying, “A post antibiotic era- in which common 
infections and minor injuries can kill, far from being an apocalyptic fantasy, is instead a very 
real possibility for the 21st century” (WHO, 2014). Even though we are currently still able to 
effectively treat most bacterial infections the fears of a post antibiotic era are quickly 
becoming a reality with the first case of Acinebacter baumannii displaying resistance to ‘last 
resort’ drug colistin (16). In 2016, a strain of Klebsiella pneumonia was isolated from an 
American woman who had recently returned from India. The strain was shown to be resistant 
to 26 antibiotics and the woman sadly died (17).  The Infectious Diseases Society of 
America has predicted that at least ten more classes of antibiotics, which are effective 
against multi-drug resistant bacteria, are needed within the next 10 years to keep the issue 
of resistance under control (18). However, this will only be a short-term fix and new methods 
are needed to overcome the problem of antibiotic resistance in the long-term. Unfortunately 
current avenues, such as the genomic approach, to discovering new classes of antibiotics 
are yet to provide any results (19). A possible option is to explore ecological niches, such 
as the marine environment, to try and uncover novel antimicrobials (20, 21). 
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1.3 Mechanisms of Resistance  
Bacteria can acquire resistance to antibiotics in two ways: through point mutations and 
through horizontal acquisition of resistance genes. Horizontal gene transfer occurs through 
three main mechanisms: conjugation (via plasmids and conjugative transposons), 
transduction (bacteriophages) and transformation (uptake and incorporation of extracellular 
DNA) (22). Acquisition of different resistance genes or altering genetic material can result in 
different resistance mechanisms. Some resistance genes encode enzymes which degrade 
antibiotics before they can have an effect, e.g. Pseudomonas aeruginosa produces AmpC 
β-lactamase which inhibits penicillin and cephalosporins which induce the enzyme (23). 
Another mechanism of resistance is altering the target or binding site, for example the penA 
gene encodes an altered penicillin-binding-protein (PBP)-2 in penicillin resistant Neisseria 
gonorrhoeae, causing a 10 fold decrease in acetylation of penicillin (24). Upregulation of 
efflux pumps is a common mechanism seen in multi-drug resistant bacteria e.g. multidrug 
transport (Mdt) A efflux pump, which is expressed in Lactococcus lactis and E. coli, that 
provides resistance to chloramphenicol, tetracycline and streptomycin (25). Downregulation, 
exchange or mutation of porins prevents antibiotics reaching intracellular targets preventing 
them for exerting an effect, for example β-lactam resistant Klebsiella pneumoniae has been 
to shown exchange the larger porin OmpK35 for the smaller porin OmpK36 preventing β-
lactam antibiotics entering the cell (26).  
Another inherent mechanism of antimicrobial resistance is the formation of a biofilm (27-29). 
Bacterial biofilms are formed from a hydrated matrix of polysaccharides and proteins which 
encase bacteria in a slimy layer (30). Bacteria which can form biofilms are often associated 
with infections caused by medical instruments such as ocular implants and prosthetic heart 
valves (29) and are also linked with diseases such as cystic fibrosis (31) and periodontitis 
(32). Pseudomonas aeruginosa, which is responsible for pneumonia, is one of the best 
known bacteria to form a biofilm (33). Antimicrobial resistance due to biofilms is different 
from the other resistance mechanisms mentioned above as it is not thought to be acquired 
through mobile genetic elements or genetic mutation (27, 30). This theory comes from the 
fact that bacteria with no known genetic basis for resistance have reduced susceptibility to 
antibiotics when growing in biofilms (30, 34), and when the biofilm is dispersed the bacteria 
rapidly becomes susceptible again (35).  One study showed bacteria surrounded by a biofilm 
could survive after treatment with antibiotics hundreds and even thousands of times the 
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minimum inhibitory concentration (MIC) (36).There are three main theories about why biofilm 
formation causes antimicrobial resistance in bacteria (27): the first is slow or incomplete 
penetration of the biofilm by the antibiotic; the second theory suggests biofilms form their 
own microenvironment which antagonises the antibiotic; the third theory is that micro-
organisms within the biofilm form a unique, highly protective, spore-like state. Infections due 
to biofilm forming bacteria can persist for months, years or even a lifetime if they can’t 
effectively be treated with antibiotics or the cause of infection can’t be removed by surgery 
(37).  
1.4 Selective Pressures for Antimicrobial Resistance 
Different anthropogenic selective pressures have rapidly increased the rate of antibiotic and 
antimicrobial resistance over the last 50 years. The most recognised selective pressure of 
antibiotic resistance is over-prescription of antibiotics in the clinic, with a strong correlation 
between antibiotic consumption and infection with resistant bacteria (38). In 2015, the 
National Institute for Health and Care Excellence (NICE) released guidelines on prescribing 
antibiotics to help preserve their future effectiveness. These guidelines included discussing 
alternative treatments with patients, not prescribing antibiotics to patients with infections 
which will likely get better on their own and if antibiotics are needed the shortest effective 
dose should be prescribed (39). However, general practitioners (GPs) are reporting pressure 
from patients to prescribe antibiotics. 45% of  GPs said they prescribed antibiotics for viral 
infection knowing they would not be effective, while 44% of GPs said they prescribed 
antibiotics to get a patient to leave their consulting room (40). However, it has been shown 
that when GPs are able to spend longer with a patient they are less likely to prescribe an 
antibiotic (41). This evidence suggests that to put a stop to the over-prescribing of antibiotics 
the public should be better educated about when antibiotics are needed and the risks of 
taking antibiotics unnecessarily e.g. for a viral infection. 
Antibiotics are also extensively used prophylactically in agriculture and aquaculture to 
promote growth of livestock and improve feed efficacy in agriculture (42, 43). Humans and 
animal have similar microbiomes meaning bacteria and bacterial resistance genes can 
readily pass between the two, for instance through human consumption of meat or fish (42). 
Antibiotics have been shown to be poorly absorbed by animal’s guts with 30%-90% of the 
parent compound being excreted (44) and as most of the drugs are water soluble 90% of 
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the active drug can be excreted in urine and 75% can be excreted through faeces (45). Land 
animal faeces and closed aquaculture systems wastewater are used as supplements in 
fertilizer which is spread over crops. This can cause the transfer of resistance genes and 
antibiotic residues to crops, soil and the aquatic environment through farm-land run off (46), 
and may subsequently impact open aquaculture system located in shallow coastal waters 
and sheltered bays (47). To try and reduce the effect agriculture has on driving antimicrobial 
resistance the Veterinary Feed Directive (VFD) was approved by the FDA in 2015 (48). The 
VFD is used to instruct veterinarians, pharmaceutical companies and producers on how to 
administer drugs in animal feed and water (48). It is also now illegal to use antimicrobial 
agents which relate to human antibiotics for anything other than to treat and prevent the 
spread of infection. In the US, producers also need a veterinary signed form to purchase, 
store and administer those drugs (48). Regulations on antimicrobial use in aquaculture vary 
dependant on location. In Europe the Veterinary Medicine Products Derivative (VMPD) 
banned the use of antibiotics to prevent disease and very few antimicrobial agents are 
licensed for the use in aquaculture to treat infection when it occurs (49). However, 90% of 
aquaculture production takes place in developing countries where there is little regulation 
on the use of antimicrobial agents. One study investigating shrimp farmers on the Thai coast 
found that 74% of farmers used antibiotics daily for pond management with over 13 different 
antibiotics being used (50). This indicates that stricter regulations and dissemination of the 
effects antibiotic use has on resistance are needed in developing countries to try and combat 
the spread of resistance genes from aquaculture.   
Another selective pressure for antimicrobial resistance is pollution from wastewater 
treatment plants (51). Resistance genes and antibiotic residues can enter aquatic 
environments through wastewater, especially from hospital waste (52). Wastewater is 
disinfected using a range of techniques including chlorination and photogeneration, which 
has been shown to remove antibiotics such as β-lactams, fluoroquinolones and tetracycline 
(53-55). Despite this, low concentrations of antibiotics and resistant bacteria have been 
found in wastewater samples released into the environment. Even at low concentrations, 
antibiotics can inhibit sensitive bacteria allowing resistant bacteria to persist in the aquatic 
environment (56). 
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1.5 Natural Antimicrobials 
In the past, antibiotics have been discovered through intensive screening of terrestrial 
organisms such as microbes, plants and animals. The bioactive compounds were then 
altered or were the basis for synthetic derivatives of new antibiotics in existing classes (57). 
However, over the last 20 years discovery of terrestrial-borne natural products with unique 
scaffolds has decreased dramatically, resulting in a lack new antibiotic classes (57, 58). This 
coupled with the rapid emergence of resistance to current antimicrobial agents has meant 
modern medicine has turned to the marine environment to search for new bioactive 
compounds and products which can work in synergy with existing drugs (57, 59). Marine 
organisms, which contribute to approximately half the world’s biodiversity, have been 
classified as the largest remaining untapped reservoir of novel compounds which have the 
potential to be developed into pharmacological agents (60). The unique bioactive 
compounds produced by marine organisms are a consequence of their harsh living 
environments, in which they must compete for space, adapt to tide variations, face high 
salinity and protect against predation (61). Previous studies have shown marine sessile 
organisms, such as sponges, coral and algae, produce peptides with diverse 
pharmacological effects including: antineoplastic agents, antimicrobial agents, HIV-
inhibitors, as well as the diagnosis and treatment of certain central nervous system disorders 
(62).  
1.6 Seaweed as a Model 
For this project we are interested in the antimicrobial effect of macroalgae (seaweeds), 
which can be classified by three groups: Rhodophyta (red seaweeds), Phaeophyceae 
(brown seaweeds) and Chlorophyta (green seaweeds). Seaweeds are constantly exposed 
to a wide range of micro-organisms that are present in the ocean, some of which are 
potentially harmful. It has therefore been hypothesised that their metabolites and secondary 
metabolites have strong antimicrobial effects to prevent disease, fouling and the settlement 
of unwanted epiphytes (63, 64). Bioactive compounds within structural elements of 
seaweeds include: alginates in brown seaweeds (64, 65), carrageenans in red seaweeds 
(64, 65), ulvans in green seaweeds (64, 66), and carotenoids which are present in all types 
of seaweeds (64, 67). Seaweed secondary metabolites which exert an antimicrobial effect 
include: lectins (68), alkaloids (69)  and terpenes (70). Studies have shown that factors such 
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as season, geographical location and age of the seaweed can affect its antimicrobial activity 
(64). 
1.7 Seaweed-Associated Bacterial Communities 
Despite seaweeds exerting antimicrobial effects they also secrete nutrients which attract the 
settlement of certain microorganisms and stimulate the formation of biofilms (71). Studies 
have shown that between 102-107 cells per cm2 can settle on seaweed, depending on 
macroalgae species, section of thallus and season (72-74). One of the first studies to 
investigate the composition of seaweed associated bacterial communities used scanning 
electron microscopy to examine the brown macroalgae Aschophyllum nodosum (75). The 
study found notable differences in bacteria populations of the hold-fast, internodal regions 
of the stipe and apical tips, with the most diverse population being found on the internodal 
regions of the stipe (75). Staufenberger et al., (2008) used denaturing gradient gel 
electrophoresis (DGGE) and 16srRNA gene clone libraries to discover that the bacterial 
communities on Laminaria saccharina were more diverse at the older blades compared to 
younger sections of the plant (76). It was hypothesised that this was due to more damaged 
cells, which are susceptible to bacterial decomposition being present in older sections of 
the macroalgae. This hypothesis is backed by previous research which showed a higher 
bacterial density on diseased or bleached macroalgae compared to healthy plants (77, 
78).  
Multiple studies have found differences in the type and abundance of bacteria which 
colonise macroalgae in different seasons, with a higher abundance and diversity of 
bacteria being observed in summer compared to winter (79-81). One study looked at the 
effect temperature had on the abundance and diversity of bacteria settled on Fucus 
vesiculosus, and found an increase in temperature increases the diversity of the bacterial 
community but not the abundance of bacteria present (82). This suggests temperature 
could be behind the change in bacterial communities from summer to winter. The same 
study also found seaweed bacterial communities are species specific (79). Another study 
found that the type of bacteria which settle on seaweed is unique to its specific ecological 
niche, independent of seaweed species  (83). However, other research has found that 
seaweed of the same species in different geographical location has more similar epiphytic 
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bacterial communities than seaweeds of differing species in the same ecological niche 
(83, 84). 
Many studies have used different culture-based and molecular techniques to investigate the 
composition of seaweed associated bacterial communities. Techniques such as 16s rRNA 
gene sequencing and before that DGGE have revealed that the most common classes of 
seaweed epiphytic bacteria include Alphaproteobacteria, Gammaproteobacteria 
Bacteroidetes, Planctomycetes and Actinobacteria (85). Despite seaweed associated 
bacterial communities vary depending on factors such as seaweed species, geography and 
temporal changes these classes have been isolated from different seaweed species from 
around the world (85). Although these different classes of bacteria have been isolated on 
green, red and brown seaweed, one review has found some bacterial classes are more 
common on some seaweed groups than others. Alphaproteobacteria  mainly isolated from 
green seaweeds, and Actinobacteria and Firmicutes are more commonly associated with 
red and brown seaweeds (86).  
One review found that only 33 different bacterial genera were detected across red, green 
and brown seaweeds, these included Bacillus, Pseudomonas and Vibrio (86), however this 
number could be an underestimation due to the majority of studies using culture-based 
techniques. The same review also found that the same species of bacteria are rarely isolated 
from different species of seaweed, even when the macroalgae are from the same genus 
(86). For example, the Flavobacteria bacterium Zobellia russellii has only been found to be 
present on Acrosiphonia sonderi, Octadecabacter antarcticus has only been isolated from 
F. vesiculosus (79) and Acinetobacter lwoffii has exclusively been identified on Ulva australis 
(86, 87). However there has been a handful of bacterial species which has been reported 
on multiple macroalgae, including seaweed from different genera (86), these include E. coli 
(88-91), Vibrio tasmaniensis (92, 93) and Bacillus licheniformis (92, 94). The variety of 
culture-based and molecular techniques used to identify seaweed associated bacteria has 
led to the discovery of over 50 new bacterial species (95). Cullulophaga baltica and 
Cellulophaga fucicola were initially discovered through 16s rDNA sequencing of bacteria 
isolated from Fucus serratus (96). Cullulophaga baltica has only shown to be present on the 
surface of F. serratus however Cellulophaga fucicola has been isolated from Ulva australis 
in addition to F. serratus (97). Pseudoalteromonas ulvae is another example of bacteria 
which was first discovered after being isolated from the surface of Ulva lactuca, (98).  
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Most of the studies characterising the epiphytic bacterial communities of seaweed have 
focused on the classification of bacteria which settle on the surface of macroalgae. However, 
one study has indicated that it may be the function of the bacteria which determines the 
seaweed microbial community rather than taxonomical group (99). Burke et al., 2011, used 
metagenomic sequencing to analyse the bacterial communities of six Ulva australis plants 
collected from the same location. They found that the functional composition of the bacterial 
communities were a lot more similar compared to the species of bacteria present on each 
sample, indicating a core set of functional genes (99). For example, proteins associated with 
flagellum-mediated motility were highly expressed in all the bacterial communities tested, 
those proteins will allow the bacteria to move towards the host and will also help with the 
formation of bacterial biofilms (99, 100). Other proteins, which are associated with the 
metabolism of water-soluble polysaccharides (e.g. rhamnose and xylose) produced 
specifically by Ulva australis, were also abundant across the bacterial communities of all six 
samples, presumably aiding adaptation to the host (99, 101). 
1.8 Local Adaptation  
Many studies have focused on the composition of microbial communities associated with 
different seaweeds and have found bacteria which settle on seaweeds are host specific (85, 
86), which could indicate the bacterial population is locally adapted to its seaweed host. 
Local adaptation is defined as a population which is fitter in its home habitat than populations 
from foreign habitats (102, 103). To our knowledge there has been no previous research 
into whether bacteria which settle on seaweeds are locally adapted, however a handful of 
studies have demonstrated local adaption of invertebrates on seaweeds (104-107). Most 
local adaption studies focus on terrestrial and aquatic environments but not many have 
looked at the marine environment. This is in part due to the pre-conceived idea that 
organisms in the marine environment evolve to have phenotypic-plasticity because of their 
hostile, ever-changing living environments (107, 108). Marine organisms are also dispersed 
over broad spaces dependent on sea currents and their ability to settle, which would indicate 
a preference to evolve more generalized (107, 109). In contrast, more recent research has 
shown that the evolution of marine organisms is a lot more restrictive and can depend on 
local currents, behaviour of the organism and its ability to find a suitable habitat (107, 109-
111).  
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1.9 Cross-Resistance 
We are interested in whether bacteria that are resistant to seaweed extracts show cross-
resistance to clinically used antibiotics.  Cross-resistance is defined as the occurrence of 
resistance to one antimicrobial agent accompanied by resistance to another distinct 
antimicrobial agent (112). Cross-resistance occurs when different antimicrobial agents 
share the same route of access into the cell or initiate a common pathway to cell death (112). 
This interaction can be seen between different classes of antibiotics as well as antibiotics 
and other substances, such as heavy metals, biocides, disinfectants or solvents (112-115). 
An example of a cross-resistance mechanism is the multi-drug resistant pump present in 
some Listeria monocytogenes strains which has the ability  export both antibiotics and heavy 
metals (116).   
Previous studies have shown seaweed extracts can inhibit human pathogens, for instance 
Sargassum vulgare ethanol extracts have shown to be effective against Klebsiella 
pneumoniae (117) and S. aureus growth is inhibited by Sargassum fusiforme diethyl ether 
(117) and Chaetomorpha aerea methanol extracts (118). These results are promising as 
they demonstrate seaweeds could be a potential avenue for the development of new 
antibiotics. However, it is important to identify whether bacteria that are resistant to 
conventional antibiotics are cross-resistant to natural antimicrobials. 
1.10 Natural Antimicrobial Resistance  
Despite human activity having huge impact on the acceleration of antimicrobial resistance, 
it is not the only relevant driver of its evolution. Phylogenetic reconstruction has revealed 
antimicrobial resistance genes have been present in the environment well before the 
introduction of antibiotics (119). For example,  protein structure-based phylogeny has been 
able to identify that serine β-lactamases originated over 2 billion ago (120), and 
metagenomic clones derived from 10,000-year-old ‘cold-seep’ sediment suggests that the 
evolution of the enzyme is ancient (121). Resistance genes have been found in pristine 
environments with no human contact or pollution from antibiotics such as ice (122), deep 
terrestrial subsurface (123), and permafrost (124), indicating the genes have not originated 
through anthropogenic activity. As genes that encode for different resistance mechanisms 
originated and evolved before the use of antimicrobial agents they could have had a different 
original purpose. Genes found in natural antimicrobial producers are likely to of evolved to 
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prevent the host being harmed by its effects, for example actinomycetes, producers of 
antibiotics such streptomycin, express aminoglycoside-modifying enzymes (125). Also, 
efflux-pumps have been shown to remove metabolites and are involved in cell signalling 
(126) and β-lactamases are involved in the biosynthesis of the cell wall (127).  
1.11 Aims and Objectives 
The aim of this project is to use both culture-dependent and culture-independent techniques 
to identify:   
 Whether seaweeds can select for human pathogens and bacteria which are resistant 
to both natural antimicrobials, in the form of seaweed extracts, and clinically used 
antibiotics. 
 Relative abundance of antibiotic resistance in seaweed-associated communities and 
characterise what resistant genes are present in the seaweed microbiome and 
whether they vary depending on seaweed species. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Culture-based Characterisation of Seaweed-Associated 
Bacteria and Their Resistance Profiles 
2.1 Introduction 
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2.1.1 Local Adaptation and Cross-resistance 
In the previous chapter we discussed the hypothesis of seaweed-associated bacterial 
communities being locally adapted to their host (see section 1.9). To our knowledge there 
has been no previous research into whether bacteria which settle on seaweeds are locally 
adapted. During this chapter we will, for the first time, measure local adaption of seaweed-
associated bacteria by testing Vibrio, E, coli and S. aureus isolated from specific seaweeds 
grow better in seaweed-based broth produced from their host species compared to media 
made from other seaweeds. We shall also use a disc diffusion assay to test whether bacterial 
strains are less susceptible to methanolic extracts derived from the seaweed species they 
were sampled from compared to extracts of different seaweed species.  
In section 1.10 we discussed bacteria being cross-resistant to both clinically used antibiotics 
and natural antimicrobials (see section 1.10).  A previous study conducted in our laboratory 
used disc diffusion assays to investigate cross-resistance and collateral sensitivity between 
methanol seaweed extracts and conventional antibiotics. A positive correlation between 
resistance to seaweed extracts and clinically used antibiotics was demonstrated by hospital 
isolated S. aureus, indicating cross-resistance (128). 48 seaweeds extracts were tested 
against 28 S. aureus. 37.5% of the seaweeds extracts were able to inhibit all the S. aureus 
strain, those extracts included: Asparagopsis armata, Cystoseira baccata, Himanthalia 
elongate, F. vesiculosus, F. serratus, Furcellaria lumbricalis and Sargassum muticum (128). 
In this chapter we shall use Vibrio, E. coli and S. aureus isolates obtained from different 
seaweed species and employ the same techniques to investigate cross-resistance towards 
clinically used antibiotics and methanol seaweed extracts. 
2.1.2 Community Resistance Assay 
We shall look at resistance to specific antibiotics in general bacteria isolated from seaweed 
as Vibrio, E. coli, S. aureus will not be the only bacteria present on the surface of our 
seaweeds. This shall be done using a community resistance assay. This will involve 
cultivating bacteria isolated from different seaweeds species on marine agar. The bacterial 
communities will be plated on plain marine agar and agar amended with antibiotics. This will 
allow to see if seaweeds select for antibiotic resistant bacteria. By investigating resistance 
to antibiotics in seaweed bacterial communities, including cross-resistance to conventional 
antibiotics and natural antimicrobials, we can determine if seaweeds are hotspots for 
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antibiotic resistant bacteria. This is important as the seaweeds we are testing are abundant 
across the UK coastline therefore humans may be exposed to them, and the antibiotic 
resistant bacteria settled on their surface, posing a potential risk to their health. If we can 
show seaweed selects for antimicrobial resistant bacteria, we can use them to determine 
which marine waters of safe for recreational use i.e waters with a high abundance of 
seaweeds may not be safe for humans.    
2.1.3 Vibrio species 
Vibrio spp are gram negative, curved rod-shaped bacteria which can be both pathogenic 
and non-pathogenic and are mainly found in marine environments (129). Vibrio species are 
commonly divided into two groups: Vibrio cholerae, responsible for cholera infections, and 
non-cholera Vibrio (130).  The most common non-cholera Vibrio species include V. 
parahaemolyticus, V. alginolyticus and V.  vulnificus (130). These species are considered 
foodborne pathogens, with V. parahaemolyticus being the leading cause of seafood-
associated bacterial gastroenteritis in the United States and making up approximately half 
of the foodborne outbreaks in some Asian countries (131). However Vibrio infections can 
also be caused by exposing open wounds to warm seawater (132). Symptoms of Vibrio 
gastroenteritis include stomach cramps, nausea, vomiting, diarrhoea and haematochezia. 
Patients presenting with a Vibrio infected wound often have an immunocompromising 
condition making it essential for quick diagnosis and treatment. The infection can often lead 
to sepsis and severe cellulitis around the abrasion. Patients should be treated with both 
doxycycline and ceftazidime, as well as direct treatment of the wound, such as drainage of 
abscesses or even amputation. However, even with efficient diagnosis and treatment 30-
40% of Vibrio infections are fatal and if infections are not treated within 72hrs the fatality rate 
can rise to 100% (133).     
The Centre for Disease Control and Prevention (CDC) have been voluntarily assessing 
culture confirmed Vibrio infections from the Gulf coast region of America since 1998, 
expanding to nation-wide in 2007. Vibrio infections have increased by 115% between 1998 
and 2010, whereas other common infection such as Shiga toxin–producing Escherichia coli, 
Campylobacter and Salmonella have decreased over the same timeframe (134). In 2011 
there were an estimated 8000 cases of Vibrio infections of which 4500 were cause by V. 
parahaemolyticus and around 100 were due to V. vulnificus, however this is thought to be 
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an underestimate due to under reporting (135). Although V. parahaemolyticus is the most 
commonly reported non-cholera infection V. vulnificus contributes to 94% of non-cholera 
Vibrio infection related deaths, this is thought to be due to Vibrio gastroenteritis going 
undiagnosed as thiosulfate-citrate-bile salts-sucrose (TCBS) medium is not routinely used 
to test stool samples (136).  
There is relatively little information on Vibrio infections in Europe as there are no regulations 
in place for Vibrio controls in seafood traded within the EU, therefore there is no legal 
obligation to test for the bacteria. This is partly due to the EU expert scientific committee on 
veterinary measures related to public health (SCVMPH) deeming current internationally 
recognised methods for monitoring Vibrio infections not fit for purpose. SCVMPH instead 
suggested V. parahaemolyticus and V.  vulnificus should be included in microbiological 
sentinel surveillance systems for infectious gastroenteritis and should be included in the 
European Network for Epidemiologic Surveillance and Control of Communicable Diseases 
(9118/98/CE) (137). Another reason there are no regulations is because incidences of Vibrio 
infection are low in Europe and the cases seen are mainly related to traveling to high risk 
areas such as the US and Asia (138). However, in recent years reports of Vibrio infections 
in countries surrounding the Baltic sea have increased (139-141). One study has suggested 
this may be due to rising sea temperatures linked to global warming (142). The Baltic sea is 
believed to be one of the largest, fastest warming, low salinity marine ecosystems on the 
earth, giving Vibrio the perfect condition to thrive (142). This coupled with the fact that more 
than 30 million people live within 50 km of the Baltic sea significantly increases the clinical 
risk of Vibrio infection (137).   
V. vulnificus has shown sensitivity to a range of antibiotics including tetracycline, 
aminoglycosides, chloramphenicol, fluoroquinolones and third generation cephalosporins 
(143-145). However, Vibrio strains CMCP6 and YJ016 contain active drug transporters, 
enzymatic-modification systems and permeases giving them the perfect tools to develop 
resistance against antimicrobial agents (146). Unfortunately, extensive use of antibiotics in 
aquaculture to prevent disease has seen a recent rise in multi-drug resistance V. 
parahaemolyticus and V. vulnificus. In the US, studies found 57%-90% of the Vibrio strains 
expressed resistance to ampicillin (146, 147) and studies in Italy also found ampicillin-
resistance in 100% of the Vibrio strains isolated (148). Ampicillin-resistant V. 
parahaemolyticus dates as far back as 1978 (149). 45% of the US Vibrio isolates were also 
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found to be resistant to three or more antibiotics including doxycycline and tetracycline, 
which are currently used to treat Vibrio infections (146), however the Italian isolates were 
susceptible to chloramphenicol and doxycycline in all its isolates (148). The worldwide 
emergence of antibiotic-resistant Vibrio proves there should be a reassessment of how 
infections are currently treated in clinics to ensure effective treatment can be maintained. 
2.1.4 Escherichia coli 
E. coli is a gram negative, facultative anaerobic, rod shaped bacteria commonly found in the 
lower gastrointestinal tract. The majority of E. coli strains are harmless and form part of 
normal, healthy gut flora. However, a few virulent strains can cause infections such as 
urinary tract infections (UTI’s), gastroenteritis and even Crohn’s disease. Faecal-oral 
transmission is the most frequent route of infection. UTI’s cause by E. coli are one of the 
most common types of infections and are often treated with antibiotics. Antibiotics used to 
treat UTI’s include trimethoprim, nitrofurantoin and broad-range antibiotics such amoxicillin 
and ampicillin (150). The high number of antibiotic prescriptions for UTI’s has contributed to 
the rapid emergence of antimicrobial resistance seen in the clinic (151, 152). For example, 
the ‘English Surveillance Programme for Antimicrbial Utilisation and Resistance’ (ESPAUR) 
found that a third of UTI samples analysed by the NHS in 2016 displayed resistance 
trimethoprim (153). This indicates more needs to be done to reduce the number of antibiotic 
prescriptions for UTI’s. One way in which this could be done is by using urine dipstick tests 
to confirm whether antibiotics are the best method of treatment (154). 
E. coli are used as bacterial indictors for contamination in aquatic environments and are 
monitored to ensure bathing waters do not pose a threat to human health (155). Increased 
levels of E. coli in marine waters have been shown to directly correlate with a higher 
prevalence of gastroenteritis seen in bathers exposed to polluted waters (156-158). Studies 
have shown the presence of E. coli in aquatic environments could be due to multiple factors. 
One study found that within 15 minutes bathers can shed up to 6x105 and colony forming 
units (CFU) of E. coli and (159). Multiple studies have been able to isolate E. coli from treated 
wastewater meaning they could potentially be released into the environment and pose a 
threat to human health (160, 161). The bacteria were also found in storm water (162) and 
streams which drain into the coast (163), giving other possible sources of contamination in 
coastal waters.  
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It was initially thought that E. coli could not survive in seawater as after exposure they could 
no longer form culturable colonies. It is now known E. coli enter a viable but nonculturable 
(VBNC) state however there is controversy about whether they pose a threat (164). Some 
studies have found that the cells are dead or cannot be resuscitated (165, 166). However, 
other evidence suggests that not only can the E. coli survive but the pathogenic strains can 
still be infective (167), meaning they could pose a threat to human health. Salinity does not 
appear to have a significant effect on the survival of E.coli in seawater (164), however many 
other factors can influence survival rates including pH, nutrient availability, temperature and 
light radiation. E. coli prefers lower, more acidic pH levels (5-0.9) meaning the neutral pH 
(7.5-8.5) of seawater has a detrimental effect on survival rates (168). Light radiation also 
has a negative effect as it leads to oxidative stress, this is especially seen in shallow waters 
(169, 170). The optimal temperature for E. coli growth in the laboratory is 37°C, however it 
has been shown that in the marine environment survival rate of the bacteria is higher at 
lower temperature (168, 171). 
2.1.5 Staphylococcus aureus 
S. aureus is a facultative anaerobic, gram positive, cocci shaped bacterium which is most 
commonly found in the nose, respiratory tract and on the skin. S. aureus commonly 
colonises the upper digestive tract and skin without issue. However pathogenic strains can 
result in infections ranging from common skin conditions, such as eczema and impetigo, to 
rarer more severe infections, such as endocarditis and pneumonia. These diseases can 
spread through close skin contact, sharing of linen, coughing, sneezing and unwashed 
hands. Like Vibrio, S. aureus is also considered a food-borne disease which is normally 
found in dairy products and processed meats which have not been handled and stored 
correctly. The bacteria produces toxins known as enterotoxins, which when consumed 
cause rapid-onset of symptoms such nausea and sickness with or without diarrhoea, these 
are normally self-limiting and rarely result in hospitalization (172). Methicillin-resistant S. 
aureus (MRSA) is a type of S. aureus which has acquired resistance to β-lactam antibiotics, 
such as methicillin and penicillin, through HGT and natural selection. When MRSA is 
exposed to methicillin the normal penicillin-binding proteins (PBP) are inactivated and taken 
over by PBP-2a, which is coded for by the MecA gene (173). PBP-2a has a low affinity for 
methicillin rendering the antibiotic useless and allowing the bacteria to multiply (173). 
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Antibiotics currently used to treat MRSA include vancomycin and the drug combination 
trimethoprim and sulfamethoxazole (174). 
High concentrations of S. aureus in coastal waters have shown to cause an increase in 
bathers contracting a skin, eye or ear infection (156, 157, 175). Bathers themselves have 
been shown to shed up to 6x106 CUF’s of S. aureus within 15 minutes of entering water. 
Like E. coli, S. aureus are also thought to enter the marine environment through 
contamination from waste water treatment plants (176), run off after storms (162) and 
streams leading to the ocean. Research investigating survival of S. aureus in marine 
environments found the bacteria favoured seawater over fresh water due to the higher 
salinity (177). It also showed S. aureus could survive up to 11 days at 13°C compared to 
only 7 days at 20°C, indicating it prefers colder climates (177, 178). 
2.1.6 Fucoxanthin 
As well as looking at cross-resistance to seaweed extracts and clinically used antibiotics in 
bacteria isolated from seaweeds we shall use a disc diffusion assay to investigate whether 
clinical S.aureus strains are cross-resistant to antibiotics and Fucoxanthin. One study found 
that Fucoxanthin is used by the brown seaweed F. vesiculosus as a chemical defence 
against microfouling (179). The same study also used anti-settlement assays to demonstrate 
Fucoxanthins ability to inhibit the settlement of bacteria isolated from F. vesiculosus, 
indicating its potential as a surface-associated antimicrobial agent (179). Fucoxanthin is a 
yellow accessory pigment commonly found in the chloroplasts of brown algae and it is one 
of the most abundant carotenoids, contributing to over 10%, in the marine environment 
(180). Due to its chemical structure (Fig 1.0), Fucoxanthin has ability to scavenge reactive 
oxygen species which contributes to its disease preventing effects (181). Peng et al (2011) 
summarised the numerous studies which have investigated its promising effects as an 
antioxidant, anti-inflammatory, anticancer, anti-obesity, antidiabetic, antiangiogenic and 
antimalaria agent (182).   
Figure 1 Chemical structure of Fucoxanthin (183) 
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2.1.7 Aims and objectives 
The aims of this chapter are to: 
 Identify whether Vibrio, E. coli and S. aureus are present on the surface of different 
seaweeds using selective agars.   
 Test if Vibrio isolated from seaweeds are locally adapted to their host species using 
a novel seaweed media assay. 
 Test if Vibrio obtained from different seaweed species show cross-resistance to 
natural antimicrobial agents and clinically used antibiotics.   
2.2 Materials and Methods  
2.2.1 Seaweed Collection 
Samples of different seaweed species were collected at multiple intervals between October 
2016 and May 2017 at Castle Beach, Falmouth (51.6719° N, 4.6954° W) and The 
Greenbank Hotel, Falmouth (50.1612° N, 5.0744° W). Each sample was placed into a sterile 
plastic bag and transported to the laboratory. The seaweeds were thoroughly inspected, and 
any necrotic areas or epiphytes were removed before being gently washed with ddH2O. 
Table 1 displays the different seaweed species, the location they were sampled and how 
they were used over the course of this project.  
 
 
Table 1. Species of seaweed used for each experiment and the location they were sampled.   
Seaweed Species Experimental Use 
Asparagopsis armata (Harpoon Weed)  
(Rhodaphyta) 
(C) 
 
 Bacterial isolation 
 Disc diffusion assay: Vibrio isolation & extract 
 Prevalence of IntI1* 
 Metagenomic sequencing* 
Calliblepharis jubata (False Eyelash 
Weed) 
(Rhodaphyta) 
(C) 
 Disc diffusion assay: extract 
 Seaweed media assay: Vibrio isolation & media  
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Corallina officinalis (Common Coral Weed) 
(Rhodaphyta) 
(C) 
 
 Bacterial isolation 
 Disc diffusion assay: Extract 
 Seaweed media assay: Vibrio isolation & media  
 Prevalence of IntI1* 
 Metagenomic sequencing* 
Cystoseira baccata (Bushy Berry Wrack) 
(Phaeophyceae) 
(C) 
 Bacterial isolation 
 Disc diffusion assay: extract 
Cystoseira tamariscifolia (Rainbow Wrack) 
(Phaeophyceae) (C) 
 Bacterial isolation 
Fucus serratus (Serrated Wrack) 
(Phaeophyceae) 
(C & GB) 
 
 Bacterial isolation (C) 
 Disc diffusion assay: Vibrio isolation & extract 
(C) 
 Seaweed media assay: Vibrio isolation & media 
(C) 
 Prevalence of IntI1* (C & GB) 
Fucus vesiculosus (Bladder Wrack) 
(Phaeophyceae) 
(C & GB) 
 Bacterial isolation (C) 
 Extract for disc diffusion assay (C) 
 Prevalence of IntI1* (C & GB) 
Furcellaria lumbricalis (Clawed Fork 
Weed) 
(Rhodaphyta) 
(C) 
 Bacterial isolation 
 Disc diffusion assay: Vibrio isolation & extract 
 Seaweed media assay: Vibrio isolation & media  
 Prevalence of IntI1* 
 Metagenomic sequencing* 
Himanthalia elongate (Thong Weed) 
(Phaeophyceae) 
(C) 
 Bacterial isolation 
 Disc diffusion assay: Vibrio isolation & extract 
 
Polyides rotundus (Discoid Fork Weed) 
(Rhodaphyta) 
(C) 
 Bacterial isolation 
 Disc diffusion assay: Vibrio isolation & extract 
 
Sargassum muticum (Wireweed) 
(Phaeophyceae) 
(C) 
 Bacterial isolation 
 Disc diffusion assay: extract 
 
Ulva lactuca (Sea Lettuce) 
(Chlorophyta) 
(C) 
 Bacterial isolation 
 Disc diffusion assay: Vibrio isolation & extract 
 Prevalence of IntI1* 
 Metagenomic sequencing* 
Rhodaphyta= red seaweeds, Phaeophyceae= brown seaweeds and Chlorophyta= green 
seaweeds. C= Castle beach, GB=Greenbank Hotel * experiments featured in chapter 2 
2.2.2 Bacterial Isolation and Culture Conditions 
Bacteria were isolated from the seaweed surface using sterile cotton swabs. 15 cm2 sections 
were swabbed for 10 seconds in three places: the tips, thallus and base of each seaweed 
sample, using a single swab. Bacteria were transferred onto selective agar by swabbing the 
agar surface for 30 seconds. Five different selective agars were used: Marine agar 
(MA2216; Difco) General marine bacteria, TCBS agar (Oxoid) for Vibrio, Chromocult® 
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(enhanced selectivity) agar for E. coli (EMD Millipore), mannitol salt agar (10 g/L proteose 
peptone (Oxoid), 1 g/L meat extract (Fluka analytical), 75 g/L sodium chloride (Fisher 
Scientific), 10 g/L D-mannitol (Sigma Aldrich), 0.025 g/L phenol red (Sigma Aldrich) and 15 
g/L agar powder (Alfa Aesar) adjusted to pH 7.4±0.2) and readymade sheep blood agar 
(Oxoid) both for S. aureus .  
2.2.3 Vibrio Freezer stocks 
After bacterial isolation from TCBS agar individual yellow and green Vibrio colonies were 
picked. V. cholerae and V. alginolyticus present as yellow colonies (184). V. 
parahaemolyticus and V.  vulnificus form green colonies (184). Isolates were incubated at 
28 °C at 180 rpm overnight in 5 ml of marine broth (MA2216; Difco). 1 ml of each overnight 
culture was centrifuged for 2 minutes at 2500 rpm and the supernatant was removed. The 
pellet was resuspended in 1 ml of 20 % glycerol solution, made from 250 µl of 80 % glycerol 
and 750 µl of marine broth (MA2216; Difco) and the glycerol stock was stored at -80 °C.  
2.2.4 S. aureus Isolates 
Eleven antibiotic resistant and susceptible S. aureus strains were obtained from Dr Ruth 
Massey (University of Bath, UK). A further seven pathogenic S. aureus strains were obtained 
from the Royal Cornwall Hospital (Truro, UK). Resistance properties of each strain can be 
found in table S1.  
2.2.5 Seaweed Extracts 
Seaweed samples were lyophilized using a freeze drier (Scanvac, Labogene) and ground 
to powder using a household spice grinder (Cookwork Coffee and Herb Grinder). 5 g of 
powder was mixed with 50 ml of 60 % methanol which was incubated for 2 hours at 40 °C 
at 100 rpm. The solution was centrifuged for 15 minutes at 2500 rpm after which the 
supernatant was decanted, evaporated overnight and resuspended in 5 ml of 60 % methanol 
(Fisher Scientific). Fucoxanthin (carotenoid antioxidant) (Sigma Aldrich) was dissolved in 
acetonitrile and diluted using ddH2O to 1600 µg/ml and 800 µg/ml.  
2.2.6 Antibiotics 
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Table 2 shows the stock concentrations, working concentrations of the different antibiotics 
and the solvents used. Antibiotics dissolved in ddH2O were sterilised using a 0.22 µm filter 
(Millex). 
Table 2. Antibiotics used for each experiment, their solvents and concentrations  
Antibiotic Supplier Stock 
Solution 
Conc. 
(mg/ml) 
Solvent Working Solution Conc. 
Vibrio 
disc 
diffusion 
assay 
(mg/L) 
(146) 
S. aureus 
disc 
diffusion 
assay 
(mg/L) 
Community 
 resistance 
assay 
(mg/L) 
Ampicillin  
sodium salt 
Sigma 
Aldrich 
10 ddH2O 4, 8, 16 - 2 
Azithromycin Sigma 
Aldrich 
10 Ethanol 2, 4, 8 - - 
Chloramphenicol Sigma 
Aldrich 
10 Ethanol 8, 16 5, 10, 20 2 
Ciprofloxacin Fluka 
analytical 
1 0.1N 
HCl 
- - 2 
Erythromycin Sigma 
Aldrich 
10 Ethanol - 2.5, 5, 10 - 
Gentamicin  
sulfate 
Amresco 10 ddH2O 2, 8, 16 - 16 
Kanamycin  
Sulfate 
Fisher 
Scientific 
10 ddH2O - 25, 50, 
100 
- 
Tetracycline 
 hydrochloride 
Fisher 
Scientific 
10 ddH2O - 2.5, 5, 10 24 
 
2.2.7 Kirby-Bauer Disc Diffusion Assay 
Vibrio isolates grown for 18 hours at 28 °C in marine broth (MA2216; Difco) and S. aureus 
strains grown for 18 hours at 37 °C in LB broth were diluted to the McFarland standard (0.5-
0.8 at 625 nm) (185) measured using a spectrophotometer (Jenway 7315, Bibby Scientific). 
1.5 ml of diluted Vibrio was added to 28.5 ml of marine agar (MA2216; Difco) and mixed 
thoroughly before pouring into square plates (Gosselin). 400 µl of S. aureus dilution was 
added to 30 ml Mueller-Hinton agar (Oxoid) and mixed thoroughly before pouring into a 
square plate (Gosselin). Whatman antibiotic assay discs (Whatman international) were 
soaked for 5 hours in seaweed extract (table 1) or antibiotics stock (table 2) and dried in a 
laminar flow hood for 15 minutes before being placed on the surface of the agar using sterile 
tweezers (186). Negative controls (60 % methanol, ethanol, ddH2O, acetonitrile and 0.1 N 
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HCl) were prepared in the same way (186). Vibrio plates were incubated overnight at 28 °C 
and S. aureus plates were incubated overnight at 37 °C. The diameter of each halo (zones 
of no bacterial growth around disc) were measured in millimetres using a ruler. 
2.2.8 Seaweed Medium Assay 
50 g (wet weight) of seaweed (table 1) was blended using a household hand blender (Braun, 
250 watt). The blended seaweed was mixed with seawater and vortexed for 5 minutes. The 
mixture was strained using a 63 µm sieve (Endecotts). The filtrate was sterilised using a 
0.22 µm filter (Millex) attached to a 10ml syringe. 200 µl of Vibrio isolate, cultured in marine 
broth (MA2216; Difco) overnight at 28 °C at 180 rpm, was added to 2 ml of seaweed medium 
and incubated for 18 hours at 28 °C at 100 rpm. Any turbidity was noted before adding        
400 µl of LB broth (Fisher Scientific) and incubating for another 18 hours under the same 
conditions. After checking for turbidity, a further 600 µl of LB broth (Fisher Scientific) and 
incubating for a further 18 hours under the same conditions. Any culture which showed 
turbidity was plated on LB agar (Fisher Scientific) and incubated overnight at 28 °C to check 
for growth.  
2.2.9 Community Resistance Assay 
15 cm2 from the tips of each seaweed, indicated in table 1, were cut and placed in 5 ml of 
marine broth (MA2216; Difco) containing 10 glass beads and vortexed for 30 seconds, after 
which the seaweed was removed. The remaining liquid was diluted 1:10 with marine broth 
(MA2216; Difco). 100 µl per plate of the diluted solution was plated onto marine agar plates 
(MA2216; Difco), amended with antibiotic (table 2) and a control plate containing no 
antibiotic. All plates were incubated for 18 hours at 28 °C before counting. Counts from 
amended plates were divided by the count from non-amended plate to calculate the 
proportion of resistant bacteria.   
 
 
2.2.10 Statistical Analysis 
All statistical tests were performed in R studio (version 1.0.153) (187). A binomial 
generalised linear model was used to identify the influencing factor on halo size. The linear 
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relationship between the number of seaweed extracts and conventional antibiotics different 
Vibrio strains were resistant to was classified using Pearson’s correlation coefficient. One-
way ANOVA, post hoc Tukey HSD tests and unpaired t-tests were used to identify significant 
differences in the average colony counts, disc diffusion assays, seaweed media assay and 
community resistance assay. Significance was tested at a 95 % confidence level. ggplot2 
(188) was used to enhance basic R graphics.   
2.3 Results 
2.3.1 Presence of E. coli, S. aureus and Vibrio on seaweeds 
The initial stage of our investigation was to isolate potential human pathogens from different 
species of seaweeds. We attempted to isolated Vibrio, E coli and S. aureus from different 
seaweed species during September 2016, November 2016 and March 2017. We were 
unable isolate any bacteria during November 2016, we could not isolate any S. aureus and 
we were only able to isolate very low number of E. coli from seaweeds samples in 
September 2016. As E. coli and S. aureus abundances seemed to be very low, we focused 
the rest of our experiments on Vibrio. Table 3 shows the average number of yellow and 
green Vibrio colonies isolated from 5 samples of different seaweed species during 
September 2016 and March 2017. Overall the average number of yellow colonies was 
higher than the average number of green colonies and there was more of both colonies 
colours in March 2017 compared to March 2017. A. armata and C. baccata had by the far 
highest number of colonies in March 2017 and Cystoseira tamariscifolia had the highest 
number of counts in September 2016. One-way ANOVA (Y: p<2.00x10-16, G: p= 1.13x10-
13, n=5, ANOVA) and a post hoc Tukey tests (p summaries in Table S2, n=5, TukeyHSD) 
were used to identify significant differences in the number of Vibrio colonies isolated from 
each seaweed species in September 2016. The same tests were also used to compare the 
number of Vibrio colonies isolated in March 2017 (Y: p<2.00x10-16, G: p<2.00x10-16, n=5, 
ANOVA, p summaries in Table S2, n=5, TukeyHSD). The average number of yellow Vibrio 
colonies isolated from Cystoseira tamariscifolia and S. muticum in September 2016 were 
significantly higher compared to the other seaweeds (p values: see Table S2, n=5 
TukeyHSD). Cystoseira tamariscifolia also had a significantly higher number of yellow 
colonies than S. muticum (p=0.00, n=5, TukeyHSD). F. serratus and C. baccata had a 
significantly greater green Vibrio colony counts than the other seaweed species sampled in 
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September 2016 (p values: see Table S2, n=5 TukeyHSD). F. serratus and C. baccata had 
statistically similar green colony counts (p=0.38, n=5, TukeyHSD).  whereas Cystoseira 
tamariscifolia showed to be significantly higher (p values: see Table S2, n=5 TukeyHSD). 
The average yellow and green colony counts from A. armata and C. officinalis in March 2017 
were significantly higher than the other seaweeds (p values: see Table S2, n=5 TukeyHSD). 
Both coloured colony counts from S. muticum were significantly different from the other 
seaweeds in March 2016 (p values: see Table S2, n=5 TukeyHSD). The exception to this 
was the green counts from C. jubata (p=0.67, n=5, TukeyHSD) and P. rotundus (p=0.09, 
n=5, TukeyHSD). The C. jubata colony counts were also statistically indistinguishable to the 
average number of colonies isolated from P. rotundus and H. elongate. The average number 
of green colonies from P. rotundus was statistically higher than the H. elongate green colony 
count. Statistical differences in the number of colonies isolated from each species of 
seaweed in September 2016 and March 2017 were tested using unpaired t-tests. The Vibrio 
colony counts from F. serratus, S. muticum and U. lactuca were significantly higher in March 
2017 compared to September 2016 (p values summarised in table S3, n=5, unpaired t-test). 
The number of green colonies isolated from F. serratus were also significantly higher in 
March 2017 than September 2016 (p=0.01, n=5, unpaired t-test). 
 
 
 
 
 
 
 
 
Table 3: Average number of Vibrio colonies isolated on TCBS agar from different seaweed species 
(five samples of each species) collected during September 2016 and March 2017.  
 Average Colony Count 
 September 2016 March 2017 
 Yellow Green Yellow Green 
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Asparagopsis armata - - 780.0 ± 25.0 146.0 ± 8.6 
Calliblepharis jubata - - 65.4 ± 4.2 25.0 ± 2.3 
Corallina officinalis - - 790.0 ± 10.2 154.0 ± 3.8 
Cystoseira baccata 27.0 ± 1.0 4.0 ± 0.6 - - 
Cystoseira tamariscifolia 536 ± 14.0 11.0 ± 0.9 - - 
Fucus serratus  14.6 ± 0.4 5.6 ± 0.2 15.6 ± 0.8 7.6 ± 0.5 
Fucus vesiculosus 6.2 ± 0.2 0.8 ± 0.3 14.8 ± 0.5 5.8 ± 0.3 
Furcellaria lumbricalis - - 32.0 ± 2.2 13.0 ± 0.4 
Himanthalia elongata 2.6 ± 0.2 1.0 ± 0.3 4.0 ± 1.0 1.0 ± 0.4 
Polyides rotundus - - 35.6 ± 1.4 19.0 ± 0.8 
Sargassum muticum 57.2 ± 1.5 1.6 ± 0.2 102.8 ± 1.5 34.4 ± 1.2 
Ulva lactuca 8.0 ± 0.3 0.6 ± 0.4 14.2 ± 0.6 4.6 ± 0.5 
Average ± SEM. – represents seaweed which were not sampled at that time. One-way ANOVA and 
post hoc Tukey HSD tests were used to identify statistical differences between counts in the same 
month (p values summarised in Table S2, n=5). Unpaired t-tests were used to compare the average 
number of Vibrio colonies isolated from a species in different months (p values summarised in Table 
S3, n=5). 
 
2.3.2 Local Adaptation 
 We used seaweed media assays to investigate local adaption of Vibrio isolated from 
different seaweed species. Table 4 shows the growth of individual yellow or green Vibrio 
strains, isolated from C. jubata, C. officinalis, C. baccata, F. serratus and F. lumbricalis, 
inoculated in seaweed media prepared from the same species. Each strain was grown over 
four days. On day one 200 µl of LB broth was added to the seaweed media, on day two a 
further 400 µl of LB broth was added, then on day three 600 µl of LB broth was added. On 
day four we plated the mixture on LB agar. This four-day approach was done due to the lack 
of growth observed in the first couple of days. We were unable to demonstrate local 
adaptation due to difficulty in growing Vibrio strains in the seaweed media. None of the 
isolate grew in the seaweed media prepared from F. lumricalis or C. officinalis. There was 
growth of yellow and green Vibrio observed in the C. jubata and C. Baccata media. However, 
the Vibrio isolated from F. serratus and the yellow strain isolated from F. lumbricalis did not 
grow in the C. jubata media and Vibrio from C. officinalis did not grow in the C. baccata 
media. The green Vibrio isolated from C. baccata was the only to grow in the F. serratus 
media. 
 
Table 4: Growth of a yellow and a green Vibrio strain, isolated from different seaweed 
species, in various 2 ml seaweed medias over four days 
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   Seaweed Media 
   Callibleph
aris jubata 
Corallina 
officinalis 
 
Cystoseira 
baccata 
 
Fucus 
serratus 
 
Furcellaria 
lumbricalis 
 
   Y G Y G Y G Y G Y G 
V
ib
ri
o
 O
ri
g
in
 
Calliblepharis 
jubata 
 
Day 1 + - - - - - - - - - 
Day 2 + + - - + + - - - - 
Day 3 + + - - + + - - - - 
Day 4 + + - - + + - - - - 
Corallina 
officinalis 
 
Day 1 + - - - - - - - - - 
Day 2 + + - - - - - - - - 
Day 3 + + - - - - - - - - 
Day 4 + + - - - - - - - - 
Cystoseira 
baccata 
 
Day 1 - - - - - - - - - - 
Day 2 - + - - + + - - - - 
Day 3 + + - - + + - + - - 
Day 4 + + - - + + - + - - 
Fucus 
serratus 
 
Day 1 - - - - - - - - - - 
Day 2 - - - - + + - - - - 
Day 3 - - - - + + - - - - 
Day 4 - - - - + + - - - - 
Furcellaria 
lumbricalis 
 
Day 1 - - - - - - - - - - 
Day 2 - + - - + + - - - - 
Day 3 - + - - + + - - - - 
Day 4 - + - - + + - - - - 
Day 1=+200µl LB broth, day 2=+400µl LB broth, day 3=+600µl LB broth and day 4=plated 
on LB agar) + indicates growth. – indicates no growth. Y=yellow colonies, G=green colonies. 
 
Another way we looked at local adaption was by investigating whether Vibrio strains isolated 
from seaweed were less sensitive to methanol extracts of their host seaweed compared to 
extracts from other seaweeds. Figure 2 displays the effects of A: A. armata, B: F. lumbricalis, 
C: P. rotundus and D: U. lactuca extracts on green and yellow Vibrio isolated from: A. 
armata, F. lumbricalis, P. rotundus and U. lactuca. Again, we were unable to show local 
adaptation of bacteria isolated from seaweed. Bacteria isolated from U. lactuca displayed 
the opposite effect to cross-resistance, as isolates from other seaweed were resistant to the 
U. lactuca extract whereas both green and yellow Vibrio isolated from the seaweed were 
susceptible to the extract (Figure 2D). All the Vibrio isolates tested were highly susceptible 
to A. armata, with average halo sizes > 10 mm (Figure 2A). Vibrio colonies isolated from P. 
rotundus were the only isolates resistant, except for yellow F. lumbricalis isolates, to the P. 
rotundus extract which could indicate local adaptation. However, the isolates were also 
resistant to F. lumbricalis and U. lactuca extracts. One-way ANOVA found there were no 
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significant differences between the average halo sizes caused by the inhibitory of specific 
seaweed extracts on green and yellow Vibrio isolated from different seaweeds (p values 
summarised in Table S2, ANOVA).  
 
   
 
 
 
 
 
 
 
 
 
Figure 2 
Bar chart showing the average halo sizes cause by A Asparagopsis armata; B Furcellaria 
lumbricalis; C Himanthalia elongate and D Ulva lactuca inhibiting the growth of yellow and green 
Vibrio strains (n=number of isolates) isolated from Asparagopsis armata (G: n=8, Y: n=7), Furcellaria 
lumbricalis (G: n=8, Y: n=1), Polyides rotundus (G: n=8, Y: n=7) and Ulva lactuca (G: n=7, Y: n=7). 
One-way ANOVA was used to identify significant differences in halo size of green and yellow vibrio 
colonies isolated from the different seaweed species in response to each seaweed extract (A: G: 
p=0.69, Y: p=0.20, B: G: p=0.11, Y: p=0.19 C: G: p=0.06, Y: p=0.47 D: G: p=0.34, Y: p=0.22, 
ANOVA).  
 
 
 
2.3.2 Cross-resistance Between Clinically used Antibiotics and Seaweed Extracts 
A Vibrio Resistance to Asparagopsis armata B Vibrio Resistance to Furcellaria lumbricalis 
C Vibrio Resistance to Polyides rotundus    D Vibrio Resistance to Ulva lactuca 
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We investigated cross-resistance of Vibrio isolated from different seaweeds (Table 1) to 
conventional antibiotics (Table 2) and seaweed extracts (Table 1) using a disc diffusion 
assay. Figure 3 displays the correlation between the number of clinically used antibiotics 
(four classes at different concentration, total=eleven) and seaweed extracts (total=11) each 
Vibrio isolate (green= 38, yellow=27) showed resistance to in the disc diffusion assay. 
Pearson’s correlation coefficient showed a significant positive correlation between 
resistance to seaweed extracts and clinically used antibiotics (r=0.24, p=0.05, n=65, 
Pearson’s), indicating cross-resistance. All isolates were resistant to at least two seaweed 
extracts and six out of the eleven different concentrations of antibiotics used. Only one of 
the 65 Vibrio strains was resistant to all four antibiotics at the highest concentrations we 
used. None of the isolates were resistant to all the seaweed extracts. Most of strains were 
resistant to more antibiotic concentrations than seaweed extracts. On average, the Vibrio 
strains tested were resistant to 8.57 ± 0.82 (SD) of the total number antibiotics 
concentrations used (Table 2) and 5.37 ± 2.19 (SD) seaweed extracts (Table 1). The 
standard deviations demonstrate that there is more variation in the number of seaweed 
extracts each Vibrio isolate was resistant to compared to the number of conventional 
antibiotics. 
Figure 3 
Scatter graph displaying the total number of seaweed extracts (Table 1) and clinically used 
antibiotics (Table 2) Vibrio isolates used for the disc diffusion were resistant to (n=65). Pearson’s 
coefficient used to determine correlation (r=0.24, p=0.05, n=65). The shade of each dot represents 
the number of isolates with that resistance profile, darker dots=more isolates (min=1, max=9). 
Number of Clinical Antibiotics 
38 
 
 
We used a binomial generalised linear model (GLM) to identify whether colony colour, 
antimicrobial agent or a combination of both factors had a significant effect on halo size. 
Colony colour (p=0.13, n=44, binomial GLM) and a combination of colony colour and 
antimicrobial agent (p=0.44, n=44, binomial GLM) did not have a significant effect on halo 
size, whereas antimicrobial agent did have a significant effect (p<2x10-16, n=44, binomial 
GLM). Therefore, we investigated the effects of different antimicrobial agents further. Figure 
2.1 displays the average halo sizes produced by green (Fig 2.1A) and yellow Vibrio (Fig 
2.1B) colonies in response to clinically used antibiotics and seaweed extracts. Overall, both 
colony types were resistant to more antibiotics than seaweed extracts. High levels of 
resistance (average halo size<2.11±1.04 mm (SEM)) were observed towards: azithromycin 
2 mg/L, azithromycin 4 mg/L, ampicillin 4 mg/L, ampicillin 8 mg/L, ampicillin 16 mg/L, 
gentamicin 2 mg/L, gentamicin 8 mg/L, gentamicin 16 mg/L, C. officinalis and U. lactuca. 
Both colonies types were highly susceptible (average halo size>9.79±1.19 mm (SEM)) to: 
Chloramphenicol 8 mg/L, Chloramphenicol 16 mg/L, A. armata, C. baccata, F. serratus, F. 
vesiculosus and Himanthalia elongata. Susceptibility to each antimicrobial agent was 
roughly the same for both yellow and green colonies, except for azithromycin 8 mg/L and F. 
lumbricalis. In figure 2.1A the average halo sized produced by azithromycin 8 mg/L 
(4.59±1.39 mm (SEM)) and F. lumbricalis (3.26±0.98 mm (SEM)) was larger compared to 
the halo size produced the same agents in figure 2.1B, 2.29±0.80 mm (SEM) and 1.47±0.60 
mm (SEM) respectively. One-way ANOVA (A: p<2x10-16, n=38, B: p<2x10-16, n=27, ANOVA) 
and post hoc Tukey HSD tests were performed for both colony types to identify significant 
differences in halo size caused by each antimicrobial agent. Lower case letters were used 
to highlight antimicrobial agents which were not significantly different from each other. 
Results from the post hoc Tukey HSD test are summarised in Table S2
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Figure 4 
Bar charts displaying the average halo size (mm) produced by green (A) and yellow (B) Vibrio 
colonies in response to different antimicrobial agents. One-way ANOVA (A: p<2x10-16, n=38, B: 
p<2x10-16, n=27, ANOVA) and post hoc Tukey HSD test (p values summarised in table S2) used to 
detect significant differences. a, b, c and d represent antimicrobial agents which do not have 
significantly different effects on green vibrio colonies. e, f, g and h represent antimicrobial agents 
which do not have significantly different effects on yellow vibrio colonies. 
 
 A       Inhibitory Effects of Antimicrobial Agents on Green Vibrio Colonies 
 C 
 B       Inhibitory Effects of Antimicrobial Agents on Yellow Vibrio Colonies 
 C 
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2.3.3 S. aureus Resistance to Fucoxanthin 
We used a disc diffusion assay to look at the resistance profiles of 18 clinical S. aureus 
strains to different conventional antibiotics of varying concentrations (Table 2) and two 
concentrations (800 mg/L and 1600 mg/L) of Fucoxanthin, a yellow accessory pigment found 
in brown algae. Figure 5 displays the results of that disc diffusion. All the S. aureus strains 
were resistant to Fucoxanthin and the majority were not susceptible to the lower 
concentrations of chloramphenicol. Around half of the strains were not susceptible to all 
three erythromycin concentrations and 2.5 mg/L of tetracycline. None of the isolates were 
resistant to kanamycin at the concentrations used (Table 2). A One-way ANOVA (p<2x10-
16, n=3) and post hoc Tukey HSD test (p values summarised in Table S2) were used to 
examine significant differences in the number of S. aureus isolates each antimicrobial agent 
could inhibit. The average number of S. aureus strains sensitive to tetracycline 2.5 mg/L and 
tetracycline 5 mg/L were significantly different from all the other antimicrobial agents and 
each other (p values summarised in Table S2). Susceptibility to tetracycline 10 mg/L and 
kanamycin was statistically indistinguishable, as was susceptibility to chloramphenicol 20 
mg/L and erythromycin (p values summarised in Table S2). Chloramphenicol 5mg/L and 
10mg/L had statistically indistinguishable numbers of sensitive S. aureus strains as 
Fucoxanthin (p values summarised in Table S2).  
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Figure 5  
Bar chart displaying the average number of S. aureus strains (out of 18) susceptible to different 
clinically used antibiotics and fucoxanthin. A one-way ANOVA (p<2x10-16, n=3, ANOVA) and post 
hoc Tukey HSD test (p values summarised in table S2, n=3) were used to test for significant 
differences between susceptibility to each antimicrobial agent. a, b, c, d and e signify the agents 
which were statistically similar.   
 
2.3.4 Clinically used Antibiotic Resistance in Seaweed-Associated Bacteria 
To extend our findings on AMR on seaweed-associated bacteria we also wanted to 
investigate antibiotic resistance of general bacterial communities isolated from different 
species of seaweed. This was done by isolating bacteria from seaweed on marine agar with 
and without antibiotics (Table 2). Figure 6 displays the proportion of bacteria resistant to 
ampicillin (2 mg/L), chloramphenicol (2 mg/L), ciprofloxacin (2 mg/L), gentamicin (16 mg/L) 
and tetracycline (24 mg/L) isolated from C. officinalis (A), F. lumbricalis (B) and U. lactuca 
(C). We also attempted to isolate antibiotic resistant bacteria from A. armata but found no 
resistance to any of the conventional antibiotics we used. One-way ANOVA and a post hoc 
TukeyHSD tests were used find significant differences between the proportion of bacteria 
resistant to different antibiotics isolated from specific seaweeds (p= Table S2, n=6, ANOVA 
and TukeyHSD). We used the same statistical tests to compare significant differences 
a 
 
b 
d d d 
c c c 
e e 
 
c 
d 
e 
e 
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between the proportion of bacteria resistant to a specific antibiotic isolated from different 
species of seaweeds (p= Table S2, n=6, ANOVA and TukeyHSD). There were very low 
proportions of ciprofloxacin and chloramphenicol resistant bacteria which were statistically 
similar for all three seaweeds (ciprofloxacin: p=0.30, chloramphenicol: p=0.09, n=6, 
ANOVA). The proportion of bacteria resistant to ampicillin and gentamicin was statically 
indistinguishable on all three seaweeds (p= Table S2, n=2, TukeyHSD). However, ampicillin 
resistance in U. lactuca associated bacteria was statistically higher than that in bacteria 
isolated from C. officinalis and F. lumbricalis. x and y. Surprisingly, the proportion of 
ampicillin resistant bacteria isolated from U. lactuca and the proportion of tetracycline 
resistant bacteria isolated from all three seaweeds exceeded one. This means the presence 
of tetracycline, and ampicillin for bacteria isolated from U. lactuca, increased the number of 
colonies which grew compared to the plates with no antibiotic.  
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Figure 6 
The proportion of antibiotic resistant bacteria isolated from three different seaweed species: A 
Corallina officinalis, B Furcellaria lumbricalis and C Ulva lactuca. One-way ANOVA (A: p=2.48x10-8, 
C: p=1.83x10-11, D: p=1.33x10-5, n=6, ANOVA) and post hoc Tukey HSD tests were used to identify 
significant difference in the proportion of bacteria resistant to different antibiotics isolated from a 
seaweed species (p= table S2, n=6, Tukey HSD). B: * signifies statistically different result. C: a, b 
and c indicate proportions which are statistically indistinguishable. D: d, e and f indicate proportions 
which are statistically indistinguishable.   One-way ANOVA (amp: p= 0.01, chlor: p= 0.09, cip: p= 
0.30, gent: p= 0.30 and tet: p= 0.04, n=6, ANOVA) and post hoc-Tuckey tests were also used to 
compare the proportion of bacteria resistant a single antibiotic isolated from multiple seaweeds (p= 
table S2, n=6, Tukey HSD). 
 
 
 
 
 
 
A   Proportion of Resistant Bacteria Isolated from 
Corallina officinalis 
* 
B Proportion of Resistant Bacteria Isolated 
from Furcellaria lumbricalis 
C Proportion of Resistant Bacteria Isolated 
from Ulva lactuca 
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2.4 Discussion 
2.4.1 Isolation of Human Pathogens from The Surface of Seaweeds 
Our first aim was to try and isolate potential human pathogens, specifically Vibrio, E. coli 
and S. aureus, from the surface of seaweeds using culture-based techniques. We sampled 
different seaweeds species at different times of the year (September, November and 
March). We were able to isolate Vibrio from all the seaweeds sampled, but we were unable 
to isolate S. aureus and could only grow very low number of E. coli.  Previous studies in our 
laboratory have looked at the effects of seaweed extracts on clinical S. aureus strains (128), 
for this investigation we wanted to see if S. aureus found in the marine environment is cross-
resistant to clinically used antibiotics and natural antimicrobials, however we were unable to 
cultivate any of the bacteria. To our knowledge, S. aureus has never previously been 
identified in seaweed associated bacterial communities which is surprising due to its high 
salt tolerance (177).  There were also very few E. coli colonies isolated from the different 
seaweed species. E. coli has been identified in the bacterial communities of multiple 
seaweed species (86, 88-91, 189) and so the inability to isolate this species is also 
somewhat surprising. However, we sampled the seaweeds from Castle Beach which is 
thought to be a relatively ‘clean’ beach, i.e. it is not in close proximality to any wastewater 
treatment plants. Therefore, we would expect very low levels of S. aureus and E. coli to be 
present in the water surrounding the seaweed meaning the bacteria is not available to settle 
on the macroalgae. Other studies also have shown difficulty isolating E. coli from marine 
environments using standard laboratory media (164, 190-192), which could explain the 
relatively low E. coli colony count. 
We were able to isolate varying numbers of Vibrio colonies from different seaweeds in both 
September 2016 and March 2017. Many studies have previously isolated Vibrio spp. from 
multiple seaweed species, including Corallina sp., Ulva sp., Fucus spp. and Sargassum sp. 
(193-196). The Vibrio colony count from each seaweed species was higher in March 2017 
compared September 2016, this could be due to the change in season, which previously 
has been shown to alter seaweed bacterial communities (79-81). The highest number of   
colonies were isolated from A. armata C. officinalis, C. baccata and S. muticum. This could 
be due to the shape of those seaweed species. A. armata and C. officinalis have lots of 
small, fine branches and C. baccata and S. muticum have small air bladders on their 
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branches. This means when we swabbed the 15cm2 section of those seaweeds a higher 
surface area was covered, equating to more bacteria, compared to seaweed with large flat 
blades. We attempted to identify the specific Vibrio spp. we isolated using Sanger 
sequencing of the 16s rRNA gene. Unfortunately, this method failed therefore we continued 
to use colony colour to distinguish between the different Vibrios used in our experiments.  
Our approach could have been improved by sampling all the seaweed species examined at 
all three timepoints. However, not all the seaweed species were available for sampling at 
each timepoint, due to seasonal changes in macroalgae. If we had more time we could have 
sampled the same seaweed species during the same months but a year later. This would 
have allowed us to see if the abundance of bacteria on the surface of different seaweeds 
follows a yearly pattern, like the trend observed in Lachnit et al., (2011) for  F. serratus (99). 
We will complement the culture-based approach with culture-independent approaches 
(metagenomic sequencing) in the following chapter.  
2.4.2 Local adaptation of Seaweed-associated Bacterial Communities 
This was, to our knowledge, the first-time local adaption of seaweed associated bacterial 
communities has been tested therefore there were no previously established methods. We 
used both a seaweed media assay and a disc diffusion assay, but we were unable to show 
local adaption of bacteria settled on the surface of different seaweed species. Seaweed 
extracts have different physiological and chemical properties to fresh seaweeds, this is also 
true for the seaweed media. Therefore, the results of both seaweed media assay and disc 
diffusion assay may not truly reflect whether bacteria are locally adapted to seaweeds in the 
natural environment. The most accurate way to study local adaptation would be to see if 
bacteria isolated from one seaweed species could settle on other seaweed species in the 
marine environment, however this would be practically challenging. To recreate the marine 
environment microcosms containing seawater and seaweed could be used. An alternative 
method to study local adaption could be to use a settlement assay similar to the one used 
in Saha et al., 2011 (179). This could be done using bioactive compounds which allow 
bacteria to settle on specific seaweeds, such as Fucoidan (85, 197-199). Fucoidan is a 
polysaccharide commonly found in brown seaweeds which attract the settlement of 
fucoidanase bacteria such as Verrucomicrobia (85, 197-199).  
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2.4.3 Antimicrobial resistance in Seaweed-associated Bacteria  
We used disc diffusion assays and a community resistance assay to test for antimicrobial 
resistance in seaweed associated bacterial communities. We found a positive correlation 
between resistance to conventional antibiotics and resistance to natural antimicrobials in 
Vibrio spp. isolated from seaweeds, which is consistent with cross resistance. Our results 
reflect those of Colclough et al., (128), and are suggestive that seaweeds can select for 
bacteria that are resistant to their secondary metabolites and that these same bacteria are 
also more resistant to clinically used antibiotics. These results have possible implications for 
human health. Potential cross-resistant pathogens settled on the surface of seaweeds may 
spread resistance genes to other bacteria colonising the macroalgae or to bacteria present 
in the surrounding water through horizontal gene transfer. Humans may be exposed to those 
resistant pathogens through bathing or consumption of seafood, if an infection develops 
from those pathogens it will make treatment difficult thus resulting in a major health risk (131, 
167).  
We could also use our results to identify seaweed species which have the potential to be 
developed into new antimicrobial agents. The occurrence of resistance to some of the 
seaweed extracts tested suggests those species may not be ideal candidates for potential 
antimicrobial agents. However, both yellow and green Vibrio showed high levels of 
susceptibility to some of the brown seaweed extracts tested, such as C. baccata and the 
Fucus spp. A previous study also showed brown seaweeds in general have higher 
antimicrobial activity compared to red and green macroalgae (200). Fucoxanthin is a 
carotenoid commonly found in brown seaweeds which has previously shown to inhibit the 
settlement of bacteria on F. serratus (179). Here, we tested the antimicrobial properties of 
fucoxanthin against clinical S. aureus strains resistant to various antibiotics. We found all 
strains were resistant to fucoxanthin at the concentration used, regardless of the resistance 
profile of the S. aureus strain. Although the pigment has anti-settlement properties, it is 
probably not behind the antimicrobial activity of brown seaweeds observed in the disc 
diffusion assays. 
Both the disc diffusion assay testing different seaweeds and antibiotic classes against Vibrio 
and the assay testing fucoxanthin against S. aureus had the limitation of only testing one 
genus or species of bacteria. It would be beneficial to investigate the effects of brown algae 
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extracts and fucoxanthin against multiple bacterial species from both clinical and 
environmental sources, to obtain a more in-depth insight into the antimicrobial activity of 
brown seaweeds. Another option could be to test the antimicrobial properties of other 
specific secondary metabolites produced by brown macroalgae. Some studies have 
identified antimicrobial activities of laminarans (201) and phlorotannins (202), which are 
secondary metabolites specific to brown seaweeds. 
Bacteria resistant to antibiotics were observed in the microbial communities isolated from 
different seaweed species tested in the community resistance assay. Over all, we found that 
bacteria isolated from different seaweed species are generally more susceptible to the same 
classes of antibiotics. The results reflected the resistance and susceptibility profiles of the 
Vibrio spp. tested in the disc diffusion assay.  This suggests that the bacteria which grew on 
the marine agar were predominately Vibrio. To confirm this, we could have re-plated the 
bacteria on TCBS agar. The microbial communities isolated from all four seaweeds had very 
low numbers of bacteria resistant to chloramphenicol and ciprofloxacin. This suggests that 
chloramphenicol and ciprofloxacin resistant bacteria are either unable to colonise the 
seaweeds sampled or they are generally rare in the marine environment. To examine these 
ideas we could have used the community resistance assay to test for resistant bacteria in 
the water surrounding the seaweed samples or used a microbial inhibition assay to test for 
chloramphenicol and ciprofloxacin residues at the sampling site (203). The presence of 
tetracycline showed an overall increase in counts in three of the four seaweed culturable 
microbiomes. Tetracycline has previously been shown to cause a hormetic, unexpected 
growth stimulating, response in E. coli at low concentrations (204), which could explain our 
results. It would be interesting to plate the same bacteria on agar containing lower or higher 
concentrations of tetracycline to see if there is still an overall increase in bacterial growth.   
Bacteria isolated from A. armata were susceptible to all the antibiotics tested as well as the 
A. armata extract. These results are surprising as we would expect the bacteria isolated 
from A. armata to be resistant to its host extract. If we assume cross-resistance, which we 
have demonstrated, we would expect the bacteria to be resistant to other antimicrobial 
agents due to the highly potent antimicrobial effects of the A. armata extract, which has 
shown to be down to it halogenated metabolites, such as bromoform and dibromoacetic acid 
(205). However, turning fresh seaweed into a methanolic extract significantly alters the 
physiological and chemical properties of the plant meaning when macroalgae is in extract 
48 
 
form it loses some of the metabolites. Therefore, the results displayed by bacteria isolated 
from A. armata may be a true representation of the bacteria in the natural environment. 
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CHAPTER 3: Characterisation of Seaweed-Associated Bacterial 
Communities and their Antibiotic Resistance Genes 
3.1 Introduction 
In the previous chapter we used culture-based techniques to identify specific pathogens 
present on the surface of seaweeds. In this chapter we use molecular techniques to 
characterise the bacterial communities of different seaweed species and identify specific 
genes present in those communities. Only a small percentage of bacteria are culturable 
(164, 190-192) and therefore we may not get an accurate representation of bacterial 
communities using purely culture-based methods. Molecular techniques have been shown 
to be better suited than culture-dependent techniques to the identification of a wide range of 
bacteria (206). It is difficult and time consuming to characterise the diverse bacterial 
phenotypes present in bacterial communities using culture-based techniques, therefore we 
shall use metagenomics during this project to characterise resistance genotypes. One gene 
we are particularly interested in is the class 1 integron-integrase gene (intI1), which we will 
quantify using qPCR.   
3.1.1 The Class 1 Integron-Integrase Gene 
The intI1 gene is one of three features which makes up the genetic platform known as an 
integron, the other two are the recombination site (attI) and promoter (PC). Integrons can 
acquire, stockpile and express exogenous genes which reside on gene cassettes, allowing 
bacteria which contain this genetic mechanism to adapt and evolve rapidly (207, 208). Class 
1 integrons are often carried on transposons and plasmids allowing rapid dissemination of 
the genes they carry throughout both gram negative and gram-positive bacteria (209, 210). 
The intI1 gene has been recovered from both environmental and clinical bacterial isolates, 
with DNA sequences from clinical settings being almost identical, suggesting that all class 
1 integrons share a common and relatively recent ancestor (209). Many of the cassettes 
carried by class 1 integrons code for antibiotic resistance determinants (211), therefore the 
intI1 gene is often used as a biomarker for antibiotic resistance. As anthropogenic factors 
have shown to be the driving force behind the increase in antimicrobial resistance (see 
section 2.4), it has been proposed the intI1 gene could also be a biomarker for human 
pollution in the environment (212). Studies have already found increased levels of the gene 
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in sewage sludge, pig slurry and run off from wastewater treatment plants (212-216), which 
have all been shown to increase levels of ARG’s in the environment.  
To our knowledge there have been no previous studies investigating the presence of the 
intI1 gene in seaweed surface associated bacteria, and there have been very few studies 
on the intI1 gene in the marine environment. One of the first studies to do so surveyed 3000 
gram-negative strains from multiple estuaries isolated over a two-month period. 3.6% of the 
isolates contained intI1, of which only 19 contained gene cassettes conferred antibiotic 
resistance (217). Another study used PCR and found 11% of E. coli isolates isolated from 
multiple estuaries in France contained the intI1 gene. The class 1 integrons predominately 
contained  the dfr cassette gene, which confers resistance to trimethoprim (218). Wang et 
al., (2008) also used PCR to detect the intI1 gene in Enterobacteriaceae isolated from 
Jiaozhou Bay, China and found 68.8% of the isolated tested positive for the gene (219). The 
intI1 gene was also found to be present in gram-negative ampicillin resistant bacteria 
isolated in Ria de Aveiro, the gene was found in 29.6% of the Enterobacteriaceae isolates  
and in 21% of the Aeromonas isolates (220). We will use PCR and qPCR to quantify the 
presence of the intI1 gene in bacterial DNA isolated from the surface of different seaweed 
species. This should allow us to quantify the prevalence of antimicrobial resistant bacteria 
in seaweed associated bacterial communities. 
3.1.2 Antibiotic Resistance Genes in the Marine Environment 
There has been very little research into ARGs in the marine environment. Most of the studies 
which have been conducted have focused on resistance in aquaculture systems in Asian 
countries. One study used PCR to identify resistance genes in bacteria isolated from marine 
aquaculture sites in both Japan and Korea. 22.5% of the isolates carried tet(M), a gene 
which confers resistance to tetracycline antibiotics, with most of the isolates being Vibrio sp., 
Lactococcus garvieae or Photobacterium damsel (221). Tet(S), another tetracycline 
resistance gene, was also detected in Vibrio sp. sampled in Korea (221). Nonaka et al., 
(2007) also used PCR and 16s rDNA sequencing to analyse bacteria sampled from 
aquaculture sites in Japan and found the presence of tet(M) in Vibrio sp. (222). The bacteria 
were collected from a site which had used oxytetracycline therapy 92 days before sampling. 
Oxytetracycline is a tetracycline antibiotic which is used as a prophylactic measure in 
aquaculture (223), which may explain why there is an abundance of tetracycline resistance 
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genes present in those environments. Oxytetracycline-resistant bacteria were also detected 
in Chinese mariculture environments. The bacterial species included Vibrio, 
Pseudoaltermonas and Altermonas and contained tet(A), tet(B) and tet(M) resistance genes 
(224). The same study also detected cat II and floR genes which could be the determinates 
of the chloramphenicol-resistant Pseudoaltermonas isolated from the mariculture 
environments (224). Another study also isolated chloramphenicol-resistant bacterium from 
Chinese coastal waters. Cat I and catt III genes were detected in human pathogens such as 
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Shewanella algae (225).  
3.1.3 Metagenomic Sequencing  
Metagenomic sequencing is defined as the analysis of genetic material contained within an 
environmental sample. Previous metagenomic studies on soil samples have revealed 
culture-based techniques and PCR have overlooked huge reservoirs of ARGs in the natural 
environment (226-229), for this reason we opted to use metagenomic sequencing to 
characterise seaweed associated bacterial communities and identify any ARGs present. To 
identify ARGs within our samples we compared our sequence data to The Comprehensive 
Antibiotic Resistance Database (CARD) a reference sequence database which compiles 
data from the last five decades and provides information on antibiotics and their targets, 
antibiotic resistance genes, associated proteins and associated literature (230). All 
sequences are imported from GenBank (231) and are associated with peer reviewed 
PubMed publications, which contributes to the more than 1600 (as of 2013) known antibiotic 
resistance genes available in the database (230). CARD is preferred to other similar 
databases as it is under constant curation and has developed a new ontology to standardise 
the language used to classify and describe ARGs (230). This is important when compiling 
data from multiple sources as it allows for accurate, comparable results being returned from 
the database. The features stated above are why we selected CARD, opposed to other 
databases, as our reference sequence database for our metagenomic data.  We shall use 
Krona (232) to help present our metagenomic data. Krona is an online tool which can be 
used to visualise complex hierarchical data. Here we shall use it to explore the proportions 
of different taxonomic groups assigned to the genes present in each of our samples.      
Previous research on ARGs in the marine environment have predominately used PCR and 
16s rDNA sequencing to identify resistance genes and host species identity (221-225). 
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However, those techniques only allow the identification of known resistance genes as they 
use targeted primers. Metagenomic sequencing relies on DNA extraction directly from 
environmental samples and sequencing of a subsample of all bacteria and genes within that 
subsample, therefore it can access bacteria which may not be readily culturable on standard 
agar media. This is especially important as the vast majority of marine bacteria cannot be 
cultured using standard laboratory practice (190-192). In contrast to the above culture-based 
studies focusing specifically on fish pathogens, a more recent study used functional 
metagenomics to analyse the resistance genes present in a range of marine environments 
located around the USA (233). Only 28% of the genes classified as (potential) resistance 
genes detected were previously known from clinical studies, for example bcr (tetracycline 
resistance), sul1(sulphonamide resistance) and tem1 (beta-lactamase resistance) (233). 
The other 72% of genes detected were unassigned, of those genes 44% were categorised 
as tetracycline resistant and 27% were thought to be ampicillin resistant. This meant that 
over half the ampicillin resistant genes were classified as unknown (233). One study used 
metagenomics to identify antibiotic resistance genes in bacterial communities associated 
with Asparagopsis taxiformis and A. armata (234) and found the presence of genes 
conferring resistance to fluoroquinolones on Asparagopsis taxiformis and methicillin 
resistance on A. armata (234). In this study, we use metagenomics to characterise the 
bacterial communities present on A. armata, C. officinalis, F. lumbricalis and U. lactuca and 
identify the presence and abundance of ARG’s in those communities. 
3.1.4 Aims and Objectives  
The aims of this chapter are to: 
 Detect and quantify the prevalence of intI1 in seaweed associated bacterial 
communities using PCR and qPCR 
 Identify the presence of our focal human pathogens on different seaweed species 
and characterise any ARG’s associated seaweed bacterial communities using 
metagenomics. 
 
3.2 Methodology 
3.2.1 DNA Extraction 
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15 cm2 sections of the tip, thallus and base of each seaweed (Table 1) was swabbed for 10 
seconds using two sterile cotton swabs to obtain bacteria. Bacterial DNA was extracted 
using a QiaAMP DNA mini kit (Qiagen) following the manufacturers protocol for buccal swab 
with the following modifications (235): after the addition of protease K, the incubation time 
was increased to 60 minutes at 56 °C, and incubation with AL buffer was changed to 10 
minutes at 70 °C followed by 5 minutes at 95 °C (236). 
Quality and Quantity of DNA was measured using a NanoDrop 2000/2000c 
Spectrophometer (Thermo Scientific). All DNA samples had a concentration above 1µg/ml, 
260/280 values between 1.6-2.0 and 260/230 values between 1.9-2.3.  
3.2.2 Polymerase Chain Reaction (PCR) 
PCR reaction mix was prepared on ice and consisted of: 7.5 µl of OneTaq® Quick-Load® 
2X Master Mix with Standard Buffer (BioLabs), 0.75 µl of forward primer (able 5), 0.75 µl of 
reverse primer (table 5), 3.8µl ddH2O and 0.1 5µl of bovine serum albumin (Fluka analytical). 
2 µl of bacterial DNA was mixed with 13 µl of PCR reaction mixture. A Veriti® 96-Well 
Thermal Cycler was used to run the following programme: 95 °C for 2 minutes (one cycle), 
95 °C for 20 seconds, 55 °C for 30 seconds then 72 °C for 30 seconds (35 cycles) and then 
72 °C for 5 minutes (one cycle). 6 µl of GeneRuler 1 kb Plus DNA Ladder (Thermofisher 
scientific) was loaded into first well of 1 % agarose gel (1 g agarose (Fisher Scientific), 100 
ml of TAE buffer (Fisher Scientific) and 5 µl ethidium bromide (Fisher Scientific)). 5 µl of 
PCR mix was loaded into subsequent wells. Gel was run for 90 minutes at 80 volts. PCR 
products were imaged using a Gbox (Syngene) and captured using G box Chemi XLI 
(V1.280) (Syngene). 
 
Table 5: 10 µM of primers (Integrated DNA Technology) used to target 16s gene and intI1 gene 
for PCR and qPCR. 
Target Primer 
name 
Sequence (5’-3’)  Size (BP) Reference 
16s 1369F CGGTGAATACGTTCYCGG 124 (237) 
16s 1492R GGWTACCTTGTTACGACT 124 (237) 
intI1 intI1-LC1 GCCTTGATGTTACCCGAG AG 196 (238) 
intI1 intI1-LC5 GATCGGTCGAATGCGTGT 196 (238) 
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3.2.3 Quantitative PCR (qPCR) 
Each 20 µl qPCR reaction mixture contained: 10 µl Brilliant III Ultra-Fast SYBR® Green 
qPCR Master Mix (Agilent), 1 µl of forward primer (table 5), 1 µl of reverse primer (table 5), 
2.4 µl ddH2O, 0.6µl reference dye (Agilent) and 5µl of bacteria DNA (diluted 5-fold from 
original concentration). Reactions for each sample were performed in duplicate. A 
StepOnePlus Real-Time PCR System (Applied Biosystems) was used to run the following 
programme: holding stage: 95 °C for 20 seconds (one cycle), cycling stage: 95 °C for 10 
seconds then 60 °C for 30 seconds (50 cycles) and melt curve: 95 °C for 15 seconds, 60 °C 
for 60 seconds then 95 °C for 15 seconds (one cycle). 16s rRNA gene copy number was 
used a proxy for bacterial cell count and used to calculate prevalence of the intI1 gene. Copy 
number of each gene was determined by comparing to a standard curve, which was made 
from a serial dilution of each target gene (16s: 1x108-1x104, intI1: 5x106-5x103). 
3.2.4 Metagenomic Sequencing 
Library preparation, metagenomic sequencing and the bioinformatics was performed by Dr 
Karen Moore and Mr Paul O’Neil at the Exeter Sequencing Service & Computational Core 
Facility the University of Exeter. A Nextera XT DNA library preparation kit (Illumina) was 
used to prepare bacterial DNA isolated from three samples of four different seaweed species 
(Table 1).  
Tagmentation of Input DNA 
10 µl of tagment DNA buffer and 5µl of amplicon tagment mix were added to 5 µl of input 
DNA (1 ng total). Mixture was places in thermocycler for 5 minutes at 55 °C and then held 
until it reached 10 °C. 5 µl of neutralize tagment buffer was added to each sample and 
incubated at room temperature for 5 minutes.  
PCR Amplification   
15 µl of Nextera PCR master mix, 5 µl of a N7 index primer (Table 6) and 5µl of a S5 index 
primer (Table 6) were added to each sample. 
Table 6. N7 and S5 index primer added to each DNA sample 
Sample N7 Index Primer N7 Sequence S5 Index Primer S5 Sequence 
1 N701 TAAGGCGA S517 GCGTAAGA 
2 N702 CGTACTAG S502 CTCTCTAT 
3 N703 AGGCAGAA S503 TATCCTCT 
55 
 
4 N705 GGACTCCT S504 AGAGTAGA 
5 N709 GCTACGCT S505 GTAAGGAG 
6 N710 CGAGGCTG S506 ACTGCATA 
7 N711 AAGAGGCA S507 AAGGAGTA 
8 N712 GTAGAGGA S508 CTAAGCCT 
9 N716 ACTCGCTA S513 TCGACTAG 
10 N718 GGAGCTAC S515 TTCTAGCT 
11 N719 GCGTAGTA S516 CCTAGAGT 
12 N720 CGGAGCCT S518 CTATTAAG 
 
The following PCR programme was run: 72 °C for 3 minutes (one cycle), 95 °C for 30 
seconds (one cycle), 95 °C for 10 seconds, 55 °C for 30 seconds then 72 °C for 30 seconds 
(12 cycles) and then 72 °C for 30 seconds (one cycle). 
PCR Clean-up 
90 µl of AMPure XP beads were added to each sample and incubated for 5 minutes at room 
temperature. Samples were placed on magnet for 2 minutes, after which the supernatant 
was removed and discarded. Beads were washed by adding 200 µl of 80 % ethanol and 
leaving for 30 seconds, after which the ethanol was removed. This stage was repeated 
twice. Beads were then left at room temperature for 10 minutes. They were then 
resuspended in 10 µl resuspension buffer before being incubated for 15 minutes at room 
temperature. The resuspended beads were again placed on the magnet for a further 2 
minutes. 5 µl of the supernatant of each sample were removed and used for library pooling. 
Library Pooling and Sequencing Loading 
5 µl of supernatant of each sample were all added to a 1.5 ml Eppendorf. 576 µl of 
hybridization buffer was added to 24 µl of the pooled sample. The mixture was incubated for 
2 minutes at 96 °C before being inverted twice and placed in an ice water bath for 5 minutes. 
The pooled sample was loaded into a MiSeq reagent cartridge. The library was then 
sequenced using a MiSeq (Illumina) machine according to the MiSeq system user guide 
(239). The use of index primers in the previous step allows multiple samples to be 
sequenced at the same time. The MiSeq (Illumina) machine uses the unique index primer 
sequence attached to each sample to distinguish which read is associated with which 
sample,   
Bioinformatics 
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The raw Illumina reads were filtered then adaptor and quality trimmed (<Q20) using fastq-
mcf (ea-utils) using the following parameters: -q 20 -I 35 -k 0 -p 15 –max-ns 0 -m 1 -t 0.01. 
The trimmed reads were aligned and compared to CARD (230) using double index 
alignment of next-generation sequencing data (DIAMOND) (University of Tübingen) (240) 
Similar reads were clustered and assembled into contiguous fragments of DNA sequence 
(contigs) using SPAdes 3.11.0 (St. Petersburg State University) (241) using the k-mer 
lengths: 21, 33, 55, 77, 99, 121. Contigs <500bp were removed. Basic local alignment 
search tool (protein) (BLASTX) (242) was used to compare the contigs to the CARD 
databases. CARD contains multiple detection models: ‘homolog’ which compares sequence 
data to reference antimicrobial resistance protein data and ‘variant’ which compares 
sequence data to reference data conferring mutations and give information on host bacteria 
as mutations are often host-specific (243). Results from the CARD detection models were 
combined and any replicates or hits with an E value ≤1x10-5 (244) or an amino acid identity 
≥90% were removed (245). Krona (232) was used to assign and visualise the taxonomic 
identities of different genes present in each sample, based on the results from CARD.       
3.2.5 Statistical Analysis 
All statistical tests were performed in R studio (version 1.0.153) (187). One-way ANOVA 
and post hoc Tukey HSD tests were used to detect significant differences in the prevalence 
of the intI1 gene associated with different seaweed species from different locations and the 
average number of hits per kilobase for both the read and contig metagenomic data. 
Significance was tested at a 95 % confidence level, P<0.05 was considered a significant 
result. ggplot2 (188) was used to enhance basic R graphics. Krona was used to visualise 
the hierarchies within the metagenomic data (246). 
 
3.3 Results 
3.3.1 Abundance of IntI1 in Bacterial DNA from Seaweeds 
We used PCR and qPCR to detect and quantify the abundance of the intI1 gene used as 
biomarker for antibiotic resistance in bacterial DNA swabbed from different seaweed species 
which had been washed to ensure only the seaweed microbiome was isolated. This gave 
an indication of whether there were any genes conferring to antibiotic resistance in our 
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samples before continuing with more expensive and time-consuming methods such as 
metagenomics. Figure S1 is a visualisation of PCR reaction used to detect the number of 
16S rRNA and intI1 genes in bacterial communities recovered from: A: U. lactuca B: F. 
serratus C: F. vesiculosus, D: H. elongate and E: C. baccata. The 16S rRNA controls only 
worked for samples A, B and C. U. lactuca was the only sample to have a faint band at 
200bp, confirming the presence of the intI1 gene for bacteria isolated from U. lactuca (A2 in 
Figure S1). The intI1 gene was undetectable in bacterial DNA isolated from the other 
seaweed species. 
PCR did not allow us to quantify the abundance of the intI1 gene in bacterial DNA obtained 
from seaweeds therefore we used qPCR in addition to PCR. qPCR has a lower detection 
limit compared to PCR meaning we were able to quantify low levels of the gene. The intI1 
gene was amplified from all the seaweeds sampled. Figure 7 displays the prevalence of intI1 
in bacterial DNA isolated from different seaweed species. Bacterial DNA obtained from A. 
armata, C. officinalis and U. lactuca had a lower prevalence of the gene compared to the 
control, which was seawater sampled from the same rockpool as the seaweeds, indicating 
their bacterial communities contain a low abundance of resistance genes. The prevalence 
of the intI1 gene was highest in bacterial DNA isolated from F. serratus, followed by F. 
serratus and then F. lumbricalis. Therefore, we would expect those seaweeds to have the 
highest abundance of ARGs in their bacterial communities. A post hoc Tukey HSD test found 
the prevalence of the gene obtained from F. serratus was significantly higher than A. armata 
and U. lactuca (p= see Table S2, TukeyHSD).   
In addition to comparing the prevalence of the intI1 gene in bacterial DNA isolated from 
different seaweed, we investigated the prevalence of the gene obtained from seaweeds 
sampled from different sites. As F. serratus and F. serratus showed the highest prevalence 
of the gene we decided to compare these results to the prevalence of the gene detected in 
bacterial communities of seaweeds of the same species sampled from another location 
(Figure 8). We chose The Greenbank hotel as it is more likely be impacted by pollution than 
castle beach. We also tested for the gene in seawater sampled from The Greenbank hotel 
harbour. The prevalence of the gene obtained from all four seaweeds were relatively similar, 
despite being sampled from different locations (Figure 8). The prevalence of the intI1 gene 
was significantly higher in the water sample from The Greenbank Hotel (p= Table S2, 
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TukeyHSD). This implies that the water at The Greenbank Hotel contains more ARGs 
compared to the water at Castle Beach. 
 
 
 
 
 
 
 
Figure 7 
Prevalence of the intI1 gene obtained from bacterial DNA isolated from: Asparagopsis aramata, 
Corallina officinalis, Fucus serratus, Fucus vesiculosus, Furcellaria lumbricalis and Ulva lactuca, 
sampled from castle beach. Control= seawater. One-way ANOVA (p= 0.01, seaweed: n= 3, control: 
n=1) and a post hoc TukeyHSD test (p= see Table S2) identified significant differences in the 
prevalence of the gene obtain from different seaweeds. Statistical similarities indicated by a and b.   
 
 
 
 
 
 
 
 
Figure 8 
Prevalence of the intI1 gene in bacterial communities of Fucus serratus and Fucus vesiculosus 
sampled from Castle Beach (CB) and The Greenbank Hotel (GB). Control= seawater. One-way 
ANOVA (p= 1.41e-07, seaweed: n= 3, control: n=1) and a post hoc TukeyHSD test (p= see Table 
S2) were used to detect significant differences in the prevalence of the gene between samples. * 
indicates a significant result. 
ab 
a 
ab 
ab 
Prevalence of intI1: Seaweed species Comparison 
a 
ab 
b 
Prevalence of intI1: Sample Site Comparison 
* 
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3.3.2 Metagenomic Characterisation of Seaweed-Associated Communities 
In the previous chapter we used culture-based methods to try and isolate potential human 
pathogens from the surface of different seaweeds. However not all bacteria are culturable 
(164, 190-192) therefore we attempted to characterise the bacterial communities of different 
species using metagenomic analysis. We analysed three samples of A. armata, C. 
officinalis, F. lumbricalis and Ulva lactuca. Figure 9 and 10 show screenshots of a Krona 
plot which gives a hierarchical classification of microbiome of one of the A. armata samples. 
Figure 9 gives an overview of contigs which could be classified, the contigs which could not 
be classified were categorised under ‘no hits’. The contigs which could be assigned were 
initially classified by domain. Figure 10 gives a zoomed in view of the ‘Bacteria’ section of 
the Krona plot which uses a multi-layered approach to classify the bacteria present in the 
community, ranging from phylum to specific species. The Krona plots allowed us to identify 
and compare possible bacteria present on the different seaweed species, which is 
summarised in Table 7. Krona plots, bacterial view, for the other A. armata samples and C. 
officinalis, F. lumbricalis and U. lactuca samples can be found in the supplementary data 
(Figure S2- Figure S12). 
Table 7 gives the average percentage breakdown of the possible bacteria isolated from A. 
armata, C. officinalis, F. lumbricalis and Ulva lactuca. Initially, we looked at the percentage 
of contigs which returned a result. Roughly 80% of the contigs assembled from each sample 
gave no hits. However, the majority of the successful hits were classed as bacteria, between 
13.00 % and 17.91% ± 1.91 % of the root values of the Krona plot. The percentage of hits 
classified as Eukaryota was <1% for all the seaweed species except A. armata (2.3 % ± 
1.01%). Roughly 40% of the bacteria isolated from C. officinalis and F. lumbricalis were 
classed as Alphaproteobacteria, whereas almost 50% the bacteria isolated from A. armata 
was classed under Gammaproteobacteria. The bacterial community isolated from U. lactuca 
was more evenly spread throughout the different classes of bacteria compared to the other 
seaweed species. 33.10 % ± 3.35 % of the bacteria could not be categorised under the five 
main classes, which were more distinct in the bacterial communities of the other seaweeds. 
Betaproteobacteria made up almost 20% of the U. lactuca bacterial community, whereas it 
only contributed to roughly 5% of the bacterial communities isolated from the other seaweed 
species.  
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Between 0.5 % and 3 % of bacteria isolated from the four different seaweeds were classified 
Vibrio spp. The highest percentage of Vibrio spp was isolated from A. armata (2.10 % ± 0.87 
%). Our results suggested the presence of species with similarity to Vibrio cholerae and the 
most common non-cholera Vibrio species, V. parahaemolyticus, V. alginolyticus and V. 
vulnificus were present on all the seaweed species tested. E coli contributed <1 % of the 
bacteria isolated from A. armata and <0.3% isolated from C. officinalis, F. lumbricalis and U. 
lactuca. There was no detection of S. aureus isolated from any of the seaweed species. 
 
 
Figure 9 
Krona plot displaying an overview of the microbiome isolated from one of the three Asparagopsis 
armata samples presented at the domain level.  “No hits” is the percent of contigs which did not 
return a result 
                                     Krona Plot: Complete View 
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. 
Figure 10 
Breakdown of the bacteria isolated from one of the three Asparagopsis armata samples ranging from 
phylum to species. 
 
 
 
 
 
 
 
 
 
                         Krona Plot: ‘Bacteria’ only 
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Table 7. Average Krona plot values (% ± SEM) based on the metagenomic analysis of bacterial 
communities isolated from three Asparagopsis armata, Corallina officinalis, Furcellaria lumbricalis 
and Ulva lactuca samples 
 Percentage of Root (% ± SEM) 
  Asparagopsis 
armata 
Corallina 
officinalis 
Furcellaria 
lumbricalis 
Ulva 
lactuca 
Root No hits 84.67 ± 1.08 81.67 ± 1.91 84.00 ± 1.63 83.00 ± 1.24 
Bacteria 13.00 ± 0.00 17.33 ± 1.91 15.33 ± 1.78 15.67 ± 1.08 
Eukaryota 2.30 ± 1.10 0.57 ± 0.07 0.70 ± 0.05 0.63 ± 0.11 
 Percentage of Bacteria (% ± SEM) 
Class Gammaproteobacteria 49.67 ± 5.17 19.00 ± 3.30 20.67 ± 2.84 16.00 ± 2.45 
Alphaproteobacteria 18.00 ± 2.49 41.67 ± 3.92 37.33 ± 4.01 24.67 ± 1.51 
Betaproteobacteria 4.33 ± 0.98 5.00 ± 0.47 6.00 ± 1.41 19.67 ± 3.13 
Bacilli 10.67 ± 7.08 0.90 ± 0.08 2.33 ± 0.27 1.33 ± 0.27 
Flavobacteriia 7.00 ± 2.05 11.33 ± 1.09 18.33 ± 5.19 5.23 ± 2.19 
Other 10.33 ± 0.54 22.10 ± 1.20 15.33 ± 0.98 33.10 ± 3.35 
Vibrio cholerae 0.10 ± 0.05 0.05 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 
parahaemolyticus 0.13 ± 0.05 0.06 ± 0.00 0.06 ± 0.01 0.05 ± 0.02 
alginolyticus 0.10 ± 0.05 0.03 ± 0.01 0.05 ± 0.01 0.06 ± 0.02 
vulnificus 0.17 ± 0.07 0.07 ± 0.01 0.08 ± 0.01 0.05 ± 0.02 
Other 1.60 ± 0.69 0.69 ± 0.08 1.03 ± 0.26 0.65 ± 0.08 
Total 2.10 ± 0.87 0.90 ± 0.08 1.27 ± 0.30 0.83 ± 0.13 
 S. aureus 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
 E. coli 0.80 ± 0.49 0.13 ± 0.02 0.25 ± 0.08 0.27 ± 0.03 
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3.3.3 Characterisation of ARGs in Seaweed-Associated Communities 
To identify the presence ARGs we aligned the Illumina reads and the assembled contigs 
from all 12 of our samples to the CARD database. We initially looked at the abundance and 
diversity of ARGs in the bacterial communities associated with A. armata, C. officinalis, F. 
lumbricalis and U. lactuca. The abundance of ARGs in each sample was measured by 
dividing the number of hits returned from BLASTing Illumina reads to the CARD database 
by the total number of kilobases (KB) in the reads (Figure 11). As contigs are formed from 
clusters of similar reads it is not possible to use them to quantify the number of ARGs present 
in a sample. However, analysis of contigs do allow us to identify which ARGs are present in 
a sample, therefore we used the number of hits returned from aligning contigs with the CARD 
database over the total number of contig KBs as a measure of ARG diversity (Figure 12). A. 
armata had the highest abundance of ARGs in its bacterial community, followed by U. 
lactuca. F. lumbricalis had the lowest abundance of ARGs, which was shown to be 
significantly lower than the abundance of ARGs present in A. armata bacterial communities 
(p=0.03, n=3, TukeyHSD). The diversity of ARGs obtained from each seaweed species 
appear to be relatively similar (all around 0.0075 hits per KB). However, the large error bars, 
shown in figure 12, suggest the diversity of ARGs varies between samples of the same 
species. A. armata had the largest error bars indicating the diversity of ARGs varied more 
between those sampled compared to the other seaweed species.  
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Figure 11 
Abundance of antibiotic resistance genes (ARG)) in bacterial communities isolated from 
Asparagopsis armata, Corallina officinalis, Furcellaria lumbricalis and Ulva lactuca. Expressed as 
hits returned from aligning Illumina reads (≥90% amino acid identity, E value ≤1x10-5) over number 
of Kilo bases One-way ANOVA (p= 0.04, n=3) and a post hoc TukeyHSD (p= see Table S2) test 
found a significant difference in the abundance of ARG’s associated with different seaweed species. 
a and b group statistically similar results.  
 
Figure 12 
Diversity of antibiotic resistance genes (ARG) in bacterial assoaicted with Asparagopsis armata, 
Corallina officinalis, Furcellaria lumbricalis and Ulva lactuca. Presented as hits returned from aligning 
contigs (≥90% amino acid identity, E value ≤1x10-5) over number of Kilobases One-way ANOVA (p= 
1.00, n=3) found not signicant difference in ARG diversity.  
Abundance of Antibiotic Resistance Genes in Seaweed 
Associated Bacteria Communities 
a 
b 
ab ab 
Diversity of Antibiotic Resistance Genes in Seaweed 
Associated Bacteria Communities 
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As well as using contigs to quantitatively analyse the diversity of the ARGs in ours samples 
we used them to identify the type of resistance genes present. Figure 13 displays the 
average percentage of hits from three A. armata, C. officinalis, F. lumbricalis and U. lactuca 
samples corresponding to genes which confer resistance to specific antimicrobial agents. 
Resistance to different antimicrobial agents varied between seaweed species. Only one 
gene had a 100% similarity hit, the gene was present on A. armata and conferred resistance 
to aminocoumarins. Genes conferring resistance aminocoumarins were present in all four 
seaweed bacterial communities as were genes conferring resistance to elfamycins and 
fluoroquinolones, however the proportion of those genes differed between species.  Over 
half of the genes obtained from U. lactuca corresponded to elfamcyin resistance, whereas 
only a quarter of the genes isolated from A. armata were resistant to that antimicrobial class. 
U. lactuca was the only seaweed species to have resistance to pulvamycins, although the 
genes conferring resistance to that antimicrobial agents made up 2% of the total number of 
hits from that species of seaweed. Both U. lactuca and F. lumbricalis contained gene 
resistance to thiopeptides. Bacterial DNA isolated from F. lumbricalis did not contain genes 
which conferred resistance to rifampicins. C. officinalis was the only seaweed to have 
resistance to daptomycins, although it was also the only species to not have resistance to 
enacyloxins. 3% of the hits from the A. armata sample corresponded to genes resistant to 
Tricoslan, those gene were not found to be present on the other seaweeds.  
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Figure 13 
Pie charts showing the average (n=3) percentage of hits which correspond to resistance genes 
specific to antimicrobial agent present in bacteria isolated from: A Asparagopsis armata, B Corallina 
officinalis, C Furcellaria lumbricalis and D Ulva lactuca. 
 
3.4 Discussion 
3.4.1 Prevalence of the intI1 Gene in Seaweed-associated Bacterial Communities 
The aims of this chapter were to characterise bacteria associated with seaweed and identify 
if antibiotic resistance is present in those communities. The intI1 gene is classed as a 
biomarker for antibiotic resistance (211) therefore we used PCR and qPCR to detect and 
quantify this gene in seaweed bacterial communities to assess the levels of antibiotic 
resistant bacteria. We were able to detect and quantify the prevalence of the intI1 gene in 
bacteria obtained from different seaweeds species. The Fucus spp. had the highest 
prevalence of the intI1 gene making them the best candidates for metagenomic sequencing, 
however we were unable to isolate a high enough concentration of bacterial DNA hence why 
A Resistance Genes characterised from 
Asparagopsis armata 
B Resistance Genes Charaterised from 
Corallina officinalis 
C Resistance Genes Characterised from 
Furcellaria lumbricalis 
D Resistance Genes Charaterised 
from Ulva lactuca 
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we did not sequence those species.  Bacterial DNA isolated from A. armata had the lowest 
level of the gene which corresponds well with the fact there were no antimicrobial resistant 
bacteria obtained from A. armata (Chapter Two). We also compared prevalence of the intI1 
gene in bacterial communities isolated from Fucus spp. sampled from a ‘clean’ site, Castle 
Beach, and a ‘dirty’ site, The Greenbank Hotel. Castle Beach has relatively little 
anthropogenic pollution whereas The Greenbank Hotel Harbour is home to many boats and 
is polluted by sewage, which is why we have deemed it our ‘dirty’ site. We found the 
prevalence of the intI1 gene was significantly higher in the water sample from the dirty site 
whereas similar levels were observed for the different seaweed species at both sites. This 
result would be consistent with a scenario where seaweeds appear to have microbial 
populations that are not impacted by water quality, so the levels of resistance may be 
intrinsic rather than effected by anthropogenic pollution.  
Although there are no previous studies investigating the presence of the intI1 gene in 
seaweed associated bacteria we can compare our results to the prevalence of the gene in 
other environments. The prevalence of the intI1 gene in seaweed epiphytic bacteria was 
similar to the percentage of the gene in bacteria obtained from environments with little 
antibiotic residue contamination, such as unamended soil (0.0002 % - 0.0036 %) (213, 247) 
and river water collected upstream from a wastewater treatment plant (248). This result 
suggests the level of AMR in seaweed microbiomes is low when compared to highly 
impacted microbial communities in soil, water and sediment.  
3.4.2 Characterisation of seaweed epiphytic bacteria  
We used metagenomic analysis to characterise the bacteria present on the surface of 
different seaweed species. However due to time constraints we were unable to compare the 
composition of the bacterial communities on different samples of the same seaweed species 
and samples of different species. We used Krona plots to analyse the microbiomes 
associated with different seaweed samples. The Krona plots showed a high percentage of 
no hits across all twelve samples. A low percentage of no hits has been previously shown 
in a study analysing the microbiome of biogas (249), which was attributed to presence of 
unknown microbes. Although there is a high abundance of unknown microbes in the marine 
environment (192, 250, 251) this is probably not the sole reason behind the large percent of 
no hits in our samples, and instead is most likely due to contamination. The Krona plots 
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revealed that classes of bacteria commonly found on seaweeds (85), including 
Alphaproteobacteria, Gammaproteobacteria and Bacteroidetes were present across the 
four seaweeds species. In Chapter two we were unable to cultivate any S. aureus and had 
very low E. coli colonies counts from bacteria obtained from different seaweeds species. 
Metagenomic analysis revealed there was no S. aureus detectable in any of the bacterial 
communities isolated from the seaweeds, and only very low percentages of E. coli were 
found. We were able to cultivate Vibrio spp. and metagenomics revealed species in this 
genus were present on all the seaweed species. These results are not suggestive of the fact 
that seaweeds can act as hotspots for human pathogens.  
3.4.3 Identification of ARG’s in Seaweed Microbiomes 
In chapter one we used culture-based techniques to show bacteria isolated from seaweeds 
can be resistant to conventional antibiotics. In this chapter we will attempt to identify the 
specific genes behind the observed resistance via metagenomic sequencing. We initially 
used the number of hits per KB returned from aligning our sequence data with CARD to 
quantify the abundance and diversity of ARGs in our samples. A. armata had the highest 
abundance of ARGs in its bacterial DNA which is surprising considering the bacteria we 
isolated from this species showed very little resistance to the antibiotic we tested in chapter 
two. The diversity of ARGs was relatively similar across the four seaweeds. This could be 
due to the seaweeds being sampled from the same location and are therefore exposed to 
the same selective pressures, such as water quality. To test this, we could have used 
metagenomic analysis to identify ARG’s in bacterial communities from the same seaweed 
species sampled from different locations, however due to budget constraints we were unable 
to do this. Instead of looking at the number of hits per kilobase we could have extracted 16s 
data from our sequences, using a programme such as QIIME (252). This would allow us to 
look at the number of ARGs relative to 16s rRNA (i.e. cell number).  
The types of resistance genes present were relatively similar across all the seaweed species 
suggesting antibiotic resistant bacteria, regardless of resistance profile, will settle on 
seaweeds independent of species. Metagenomic analysis revealed genes conferring 
resistance to elfamycins, aminocoumarins and fluoroquinolones were present on all four 
seaweeds. Elfamycin antibiotics work by inhibiting elongation factor TU interfering with 
protein synthesis (253). They are not commonly used in the clinic due to a poor 
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pharmacokinetic profile and solubility (254). There has also only been one documented case 
of elfamycin resistance genes being present in a sewage treatment plant (255), making it 
unlikely that the gene to entered the natural environment through anthropogenic pollution. 
Aminocoumarin antibiotics target DNA gyrases and have a higher affinity for the enzyme 
than fluoroquinolones (256). However, like elfamycins, they are not often used in the clinic 
due to poor solubility and high toxicity (257). Both elfamycins and aminocoumarins are 
natural products produced by Streptomyces (258, 259), species of which were detected in 
the Krona analysis. This suggests either Streptomyces in seaweed populations might select 
for resistance mechanisms through antibiotic production or these genes may confer cross 
resistance to seaweed antimicrobials. This would be interesting to study further. The 3rd 
group of common resistance genes were fluoroquinolone ARGs. Fluoroquinolones are more 
widely used and their resistance genes have previously been shown to occur in aquatic 
environments (260). It is also known that Shewenella algae is the progenitor of qnrA 
fluoroquinolone resistance gene (261) and this species is a member of the Vibrio which we 
and previous studies have shown to be common on seaweeds (85, 86). Again, it would be 
interesting to investigate the fluoroquinolone resistance in the seaweed populations further 
such as which host species they are associated with and what compounds they confer 
resistance to. In chapter two, the bacteria isolated from the same seaweed species used for 
sequencing in this chapter did not appear to be ciprofloxacin resistant, which makes the 
presence of fluoroquinolone resistance genes surprising. However, we used extracts to test 
resistance in chapter two which may not be ecologically relevant. There were no ARGs 
conferring resistance to tetracycline or chloramphenicol, which previous studies have shown 
to be present in the marine environment (221-225). However, water samples in those studies 
were taken from or near aquaculture sites which use antibiotics such as oxytetracycline and 
chloramphenicol thus driving bacteria to develop resistance to those antibiotics. It would be 
interesting to sample seaweeds from those sites and use metagenomics to determine 
whether the bacterial communities settled on those seaweeds contain gene conferring 
resistant to the antibiotics used there. 
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Chapter 4: Concluding Remarks 
From our results we conclude that seaweeds, or the associated microbial communities, may 
select for bacteria which are resistant to antibiotics. However those bacteria do not differ 
depending on seaweed species and they are not locally adapted to the seaweed host 
species. It also appears that abundance and diversity of antimicrobial resistant bacteria are 
intrinsic to the seaweed host rather than being influenced by anthropogenic pollution. 
 
 
Supplementary Data 
Table S1. Minimal Inhibitory Concentrations of clinical S. aureus strains.  
Strain Location MIC (mg/L) 
Tet Ery Chlor Kan 
51 Royal Cornwall Hospital, UK - - - - 
52 Royal Cornwall Hospital, UK - - - - 
53 Royal Cornwall Hospital, UK - - - - 
57 Royal Cornwall Hospital, UK 5 - - - 
58 Royal Cornwall Hospital, UK - 5 - - 
59 Royal Cornwall Hospital, UK - - 10  
60 Royal Cornwall Hospital, UK - - - 50 
2343 University of Bath, UK 1 1 8 - 
2424 University of Bath, UK 1 0.5 8 - 
2458 University of Bath, UK 1 8 8 - 
2564 University of Bath, UK 1 1 8 - 
2636 University of Bath, UK 1 2 8 - 
3344 University of Bath, UK 1 8 4 - 
3526 University of Bath, UK 1 8 4 - 
3729 University of Bath, UK 1 1 4 - 
3737 University of Bath, UK 16 1 8 - 
3935 University of Bath, UK 1 1 8 - 
4244 University of Bath, UK 16 8 8 - 
- unknown. Tet= Tetracycline, Ery= Erythromycin, Chlor= Chloramphenicol, Kan= Kanamycin.  
 
Table S2. Summary of all results from one-way ANOVA and post hoc TukeyHSD tests. * marks a 
significant different between samples. – not significantly different 
Samples we are testing 
significance between 
Sample 
Size (n) 
ANOVA  
(p) 
TukeyHSD 
(p) 
Sig? 
Table 3. Sept 2016 Yellow Vibrio Colony Counts 
Cystoseira tamariscifolia-Cystoseira 
baccata   
5 <2x10-16 0.00 * 
Fucus serratus -Cystoseira baccata             5 <2x10-16 0.83 - 
Fucus vesiculosus-Cystoseira 
baccata           
5 <2x10-16 0.22 - 
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Himanthalia elongata-Cystoseira 
baccata        
5 <2x10-16 0.09 - 
Sargassum muticum-Cystoseira 
baccata           
5 <2x10-16 0.02 * 
Ulva lactuca-Cystoseira baccata                5 <2x10-16 0.74 - 
Fucus serratus -Cystoseira 
tamariscifolia      
5 <2x10-16 0.00 * 
Fucus vesiculosus-Cystoseira 
tamariscifolia    
5 <2x10-16 0.00 * 
Himanthalia elongata-Cystoseira 
tamariscifolia 
5 <2x10-16 0.00 * 
Sargassum muticum-Cystoseira 
tamariscifolia    
5 <2x10-16 0.00 * 
Ulva lactuca-Cystoseira 
tamariscifolia         
5 <2x10-16 0.00 * 
Fucus vesiculosus-Fucus serratus               5 <2x10-16 0.93 - 
Himanthalia elongata-Fucus 
serratus            
5 <2x10-16 0.72 - 
Sargassum muticum-Fucus 
serratus               
5 <2x10-16 0.00 * 
Ulva lactuca-Fucus serratus                    5 <2x10-16 1.00 - 
Himanthalia elongata-Fucus 
vesiculosus         
5 <2x10-16 1.00 - 
Sargassum muticum-Fucus 
vesiculosus            
5 <2x10-16 0.00 * 
Ulva lactuca-Fucus vesiculosus                 5 <2x10-16 0.97 - 
Sargassum muticum-Himanthalia 
elongata         
5 <2x10-16 0.00 * 
Ulva lactuca-Himanthalia elongata              5 <2x10-16 0.81 - 
Ulva lactuca-Sargassum muticum                 5 <2x10-16 0.00 * 
     
Table 3. Sept 2016 Green Vibrio Colony Counts 
Cystoseira tamariscifolia-Cystoseira 
baccata   
5 1.13x10-
13 
0.00 * 
Fucus serratus -Cystoseira baccata             5 1.13x10-
13 
0.38 - 
Fucus vesiculosus-Cystoseira 
baccata           
5 1.13x10-
13 
0.00 * 
Himanthalia elongata-Cystoseira 
baccata        
5 1.13x10-
13 
0.01 * 
Sargassum muticum-Cystoseira 
baccata           
5 1.13x10-
13 
0.05 - 
Ulva lactuca-Cystoseira baccata                5 1.13x10-
13 
0.00 * 
Fucus serratus -Cystoseira 
tamariscifolia      
5 1.13x10-
13 
0.00 * 
Fucus vesiculosus-Cystoseira 
tamariscifolia    
5 1.13x10-
13 
0.00 * 
Himanthalia elongata-Cystoseira 
tamariscifolia 
5 1.13x10-
13 
0.00 * 
Sargassum muticum-Cystoseira 
tamariscifolia    
5 1.13x10-
13 
0.00 * 
Ulva lactuca-Cystoseira 
tamariscifolia         
5 1.13x10-
13 
0.00 * 
Fucus vesiculosus-Fucus serratus               5 1.13x10-
13 
0.00 * 
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Himanthalia elongata-Fucus 
serratus            
5 1.13x10-
13 
0.00 * 
Sargassum muticum-Fucus 
serratus               
5 1.13x10-
13 
0.00 * 
Ulva lactuca-Fucus serratus                    5 1.13x10-
13 
0.00 * 
Himanthalia elongata-Fucus 
vesiculosus         
5 1.13x10-
13 
1.00 - 
Sargassum muticum-Fucus 
vesiculosus            
5 1.13x10-
13 
0.94 - 
Ulva lactuca-Fucus vesiculosus                 5 1.13x10-
13 
1.00 - 
Sargassum muticum-Himanthalia 
elongata         
5 1.13x10-
13 
0.98 - 
Ulva lactuca-Himanthalia elongata              5 1.13x10-
13 
1.00 - 
Ulva lactuca-Sargassum muticum                 5 1.13x10-
13 
0.84 - 
     
Table 3. March 2017 Yellow Vibrio Colony Counts 
Calliblepharis jubata-Asparagopsis 
armata     
5 <2x10-16 0.00 * 
Corallina officinalis-Asparagopsis 
armata     
5 <2x10-16 1.00 - 
Fucus serratus -Asparagopsis 
armata           
5 <2x10-16 0.00 * 
Fucus vesiculosus-Asparagopsis 
armata         
5 <2x10-16 0.00 * 
Furcellaria lumbricalis-
Asparagopsis armata   
5 <2x10-16 0.00 * 
Himanthalia elongata-Asparagopsis 
armata      
5 <2x10-16 0.00 * 
Polyides rotundus-Asparagopsis 
armata         
5 <2x10-16 0.00 * 
Sargassum muticum-Asparagopsis 
armata         
5 <2x10-16 0.00 * 
Ulva lactuca-Asparagopsis armata              5 <2x10-16 0.00 * 
Corallina officinalis-Calliblepharis 
jubata   
5 <2x10-16 0.00 * 
Fucus serratus -Calliblepharis 
jubata         
5 <2x10-16 0.02 * 
Fucus vesiculosus-Calliblepharis 
jubata       
5 <2x10-16 0.02 * 
Furcellaria lumbricalis-Calliblepharis 
jubata 
5 <2x10-16 0.34 - 
Himanthalia elongata-Calliblepharis 
jubata    
5 <2x10-16 0.00 * 
Polyides rotundus-Calliblepharis 
jubata       
5 <2x10-16 0.49 - 
Sargassum muticum-Calliblepharis 
jubata       
5 <2x10-16 0.20 - 
Ulva lactuca-Calliblepharis jubata            5 <2x10-16 0.01 * 
Fucus serratus -Corallina officinalis         5 <2x10-16 0.00 * 
Fucus vesiculosus-Corallina 
officinalis       
5 <2x10-16 0.00 * 
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Furcellaria lumbricalis-Corallina 
officinalis 
5 <2x10-16 0.00 * 
Himanthalia elongata-Corallina 
officinalis    
5 <2x10-16 0.00 * 
Polyides rotundus-Corallina 
officinalis       
5 <2x10-16 0.00 * 
Sargassum muticum-Corallina 
officinalis       
5 <2x10-16 0.00 * 
Ulva lactuca-Corallina officinalis            5 <2x10-16 0.00 * 
Fucus vesiculosus-Fucus serratus              5 <2x10-16 1.00 - 
Furcellaria lumbricalis-Fucus 
serratus        
5 <2x10-16 0.96 - 
Himanthalia elongata-Fucus 
serratus           
5 <2x10-16 1.00 - 
Polyides rotundus-Fucus serratus              5 <2x10-16 0.87 - 
Sargassum muticum-Fucus 
serratus              
5 <2x10-16 0.00 * 
Ulva lactuca-Fucus serratus                   5 <2x10-16 1.00 - 
Furcellaria lumbricalis-Fucus 
vesiculosus     
5 <2x10-16 0.96 - 
Himanthalia elongata-Fucus 
vesiculosus        
5 <2x10-16 1.00 - 
Polyides rotundus-Fucus 
vesiculosus           
5 <2x10-16 0.88 - 
Sargassum muticum-Fucus 
vesiculosus           
5 <2x10-16 0.00 * 
Ulva lactuca-Fucus vesiculosus                5 <2x10-16 1.00 - 
Himanthalia elongata-Furcellaria 
lumbricalis  
5 <2x10-16 0.58 - 
Polyides rotundus-Furcellaria 
lumbricalis     
5 <2x10-16 1.00 - 
Sargassum muticum-Furcellaria 
lumbricalis     
5 <2x10-16 0.00 * 
Ulva lactuca-Furcellaria lumbricalis          5 <2x10-16 0.76 - 
Polyides rotundus-Himanthalia 
elongata        
5 <2x10-16 0.41 - 
Sargassum muticum-Himanthalia 
elongata        
5 <2x10-16 0.00 * 
Ulva lactuca-Himanthalia elongata             5 <2x10-16 1.00 - 
Sargassum muticum-Polyides 
rotundus           
5 <2x10-16 0.00 * 
Ulva lactuca-Polyides rotundus                5 <2x10-16 0.60 - 
Ulva lactuca-Sargassum muticum                5 <2x10-16 0.00 * 
     
Table 3. March 2017 Green Vibrio Colony Counts 
Calliblepharis jubata-Asparagopsis 
armata     
5 <2x10-16 0.00 * 
Corallina officinalis-Asparagopsis 
armata     
5 <2x10-16 0.83 - 
Fucus serratus -Asparagopsis 
armata           
5 <2x10-16 0.00 * 
Fucus vesiculosus-Asparagopsis 
armata         
5 <2x10-16 0.00 * 
Furcellaria lumbricalis-
Asparagopsis armata   
5 <2x10-16 0.00 * 
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Himanthalia elongata-Asparagopsis 
armata      
5 <2x10-16 0.00 * 
Polyides rotundus-Asparagopsis 
armata         
5 <2x10-16 0.00 * 
Sargassum muticum-Asparagopsis 
armata         
5 <2x10-16 0.00 * 
Ulva lactuca-Asparagopsis armata              5 <2x10-16 0.00 * 
Corallina officinalis-Calliblepharis 
jubata   
5 <2x10-16 0.00 * 
Fucus serratus -Calliblepharis 
jubata         
5 <2x10-16 0.03 * 
Fucus vesiculosus-Calliblepharis 
jubata       
5 <2x10-16 0.01 * 
Furcellaria lumbricalis-Calliblepharis 
jubata 
5 <2x10-16 0.34 - 
Himanthalia elongata-Calliblepharis 
jubata    
5 <2x10-16 0.00 * 
Polyides rotundus-Calliblepharis 
jubata       
5 <2x10-16 0.97 - 
Sargassum muticum-Calliblepharis 
jubata       
5 <2x10-16 0.67 - 
Ulva lactuca-Calliblepharis jubata            5 <2x10-16 0.01 * 
Fucus serratus -Corallina officinalis         5 <2x10-16 0.00 * 
Fucus vesiculosus-Corallina 
officinalis       
5 <2x10-16 0.00 * 
Furcellaria lumbricalis-Corallina 
officinalis 
5 <2x10-16 0.00 * 
Himanthalia elongata-Corallina 
officinalis    
5 <2x10-16 0.00 * 
Polyides rotundus-Corallina 
officinalis       
5 <2x10-16 0.00 * 
Sargassum muticum-Corallina 
officinalis       
5 <2x10-16 0.00 * 
Ulva lactuca-Corallina officinalis            5 <2x10-16 0.00 * 
Fucus vesiculosus-Fucus serratus              5 <2x10-16 1.00 - 
Furcellaria lumbricalis-Fucus 
serratus        
5 <2x10-16 0.98 - 
Himanthalia elongata-Fucus 
serratus           
5 <2x10-16 0.94 - 
Polyides rotundus-Fucus serratus              5 <2x10-16 0.41 - 
Sargassum muticum-Fucus 
serratus              
5 <2x10-16 0.00 * 
Ulva lactuca-Fucus serratus                   5 <2x10-16 1.00 - 
Furcellaria lumbricalis-Fucus 
vesiculosus     
5 <2x10-16 0.90 - 
Himanthalia elongata-Fucus 
vesiculosus        
5 <2x10-16 0.99 - 
Polyides rotundus-Fucus 
vesiculosus           
5 <2x10-16 0.22 - 
Sargassum muticum-Fucus 
vesiculosus           
5 <2x10-16 0.00 * 
Ulva lactuca-Fucus vesiculosus                5 <2x10-16 1.00 - 
Himanthalia elongata-Furcellaria 
lumbricalis  
5 <2x10-16 0.34 - 
Polyides rotundus-Furcellaria 
lumbricalis     
5 <2x10-16 0.97 - 
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Sargassum muticum-Furcellaria 
lumbricalis     
5 <2x10-16 0.00 * 
Ulva lactuca-Furcellaria lumbricalis          5 <2x10-16 0.79 - 
Polyides rotundus-Himanthalia 
elongata        
5 <2x10-16 0.02 * 
Sargassum muticum-Himanthalia 
elongata        
5 <2x10-16 0.00 * 
Ulva lactuca-Himanthalia elongata             5 <2x10-16 1.00 - 
Sargassum muticum-Polyides 
rotundus           
5 <2x10-16 0.09 - 
Ulva lactuca-Polyides rotundus                5 <2x10-16 0.14 - 
Ulva lactuca-Sargassum muticum                5 <2x10-16 0.00 * 
     
Figure 2A. Green Vibrio Resistance to Asparagopsis armata 
N/A 8 0.69 N/A N/A 
     
Figure 2A. Yellow Vibrio Resistance to Asparagopsis armata 
N/A 7 0.20 N/A N/A 
     
Figure 2B. Green Vibrio Resistance to Furcellaria lumbricalis 
N/A 8 0.11 N/A N/A 
     
Figure 2B. Yellow Vibrio Resistance to Furcellaria lumbricalis 
N/A 1 0.19 N/A N/A 
     
Figure 2C. Green Vibrio Resistance to Polyides rotundus 
N/A 8 0.06 N/A N/A 
     
Figure 2C. Yellow Vibrio Resistance to Polyides rotundus 
N/A 7 0.47 N/A N/A 
     
Figure 2D. Green Vibrio Resistance to Ulva lactuca 
N/A 7 0.34 N/A N/A 
     
Figure 2D. Yellow Vibrio Resistance to Ulva lactuca 
N/A 7 0.22 N/A N/A 
     
Figure 4A. Antimicrobial Agents effects on Green Vibrio  
Ampicillin 4mg/L-Ampicillin 16mg/L              38 <2x10-16 1.00 - 
Ampicillin 8mg/L-Ampicillin 16mg/L              38 <2x10-16 1.00 - 
Asparagopsis armata-Ampicillin 
16mg/L           
38 <2x10-16 0.00 * 
Azithromycin 2mg/L-Ampicillin 
16mg/L            
38 <2x10-16 1.00 - 
Azithromycin 4mg/L-Ampicillin 
16mg/L            
38 <2x10-16 1.00 - 
Azithromycin 8mg/L-Ampicillin 
16mg/L            
38 <2x10-16 1.00 - 
Calliblepharis jubata-Ampicillin 
16mg/L         
38 <2x10-16 0.86 - 
Chloramphenicol 16mg/L-Ampicillin 
16mg/L        
38 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-Ampicillin 
16mg/L         
38 <2x10-16 0.00 * 
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Corallina officinalis-Ampicillin 
16mg/L         
38 <2x10-16 1.00 - 
Cystoseira baccata-Ampicillin 
16mg/L            
38 <2x10-16 0.00 * 
Fucus serratus-Ampicillin 16mg/L                38 <2x10-16 0.00 * 
Fucus vesiculosus-Ampicillin 
16mg/L             
38 <2x10-16 0.00 * 
Furcellaria lumbricalis-Ampicillin 
16mg/L       
38 <2x10-16 1.00 - 
Gentamicin  16mg/L-Ampicillin 
16mg/L            
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Ampicillin 
16mg/L              
38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Ampicillin 
16mg/L              
38 <2x10-16 1.00 - 
Himanthalia elongata-Ampicillin 
16mg/L          
38 <2x10-16 0.00 * 
Polyides rotundus-Ampicillin 
16mg/L             
38 <2x10-16 0.96 - 
Sargassum muticum-Ampicillin 
16mg/L             
38 <2x10-16 0.00 * 
Ulva lactuca-Ampicillin 16mg/L                  38 <2x10-16 1.00 - 
Ampicillin 8mg/L-Ampicillin 4mg/L               38 <2x10-16 1.00 - 
Asparagopsis armata-Ampicillin 
4mg/L            
38 <2x10-16 0.00 * 
Azithromycin 2mg/L-Ampicillin 
4mg/L             
38 <2x10-16 1.00 - 
Azithromycin 4mg/L-Ampicillin 
4mg/L             
38 <2x10-16 1.00 - 
Azithromycin 8mg/L-Ampicillin 
4mg/L             
38 <2x10-16 0.79 - 
Calliblepharis jubata-Ampicillin 
4mg/L          
38 <2x10-16 0.04 * 
Chloramphenicol 16mg/L-Ampicillin 
4mg/L         
38 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-Ampicillin 
4mg/L          
38 <2x10-16 0.00 * 
Corallina officinalis-Ampicillin 4mg/L          38 <2x10-16 1.00 - 
Cystoseira baccata-Ampicillin 
4mg/L             
38 <2x10-16 0.00 * 
Fucus serratus-Ampicillin 4mg/L                 38 <2x10-16 0.00 * 
Fucus vesiculosus-Ampicillin 4mg/L              38 <2x10-16 0.00 * 
Furcellaria lumbricalis-Ampicillin 
4mg/L        
38 <2x10-16 1.00 - 
Gentamicin  16mg/L-Ampicillin 
4mg/L             
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Ampicillin 4mg/L               38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Ampicillin 4mg/L               38 <2x10-16 1.00 - 
Himanthalia elongata-Ampicillin 
4mg/L           
38 <2x10-16 0.00 * 
Polyides rotundus-Ampicillin 4mg/L              38 <2x10-16 0.09 - 
Sargassum muticum-Ampicillin 
4mg/L              
38 <2x10-16 0.00 * 
Ulva lactuca-Ampicillin 4mg/L                   38 <2x10-16 1.00 - 
Asparagopsis armata-Ampicillin 
8mg/L            
38 <2x10-16 0.00 * 
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Azithromycin 2mg/L-Ampicillin 
8mg/L             
38 <2x10-16 1.00 - 
Azithromycin 4mg/L-Ampicillin 
8mg/L             
38 <2x10-16 1.00 - 
Azithromycin 8mg/L-Ampicillin 
8mg/L             
38 <2x10-16 0.99 - 
Calliblepharis jubata-Ampicillin 
8mg/L          
38 <2x10-16 0.20 - 
Chloramphenicol 16mg/L-Ampicillin 
8mg/L         
38 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-Ampicillin 
8mg/L          
38 <2x10-16 0.00 * 
Corallina officinalis-Ampicillin 8mg/L          38 <2x10-16 1.00 - 
Cystoseira baccata-Ampicillin 
8mg/L             
38 <2x10-16 0.00 * 
Fucus serratus-Ampicillin 8mg/L                 38 <2x10-16 0.00 * 
Fucus vesiculosus-Ampicillin 8mg/L              38 <2x10-16 0.00 * 
Furcellaria lumbricalis-Ampicillin 
8mg/L        
38 <2x10-16 1.00 - 
Gentamicin  16mg/L-Ampicillin 
8mg/L             
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Ampicillin 8mg/L               38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Ampicillin 8mg/L               38 <2x10-16 1.00 - 
Himanthalia elongata-Ampicillin 
8mg/L           
38 <2x10-16 0.00 * 
Polyides rotundus-Ampicillin 8mg/L              38 <2x10-16 0.37 - 
Sargassum muticum-Ampicillin 
8mg/L              
38 <2x10-16 0.00 * 
Ulva lactuca-Ampicillin 8mg/L                   38 <2x10-16 1.00 - 
Azithromycin 2mg/L-Asparagopsis 
armata          
38 <2x10-16 0.00 * 
Azithromycin 4mg/L-Asparagopsis 
armata          
38 <2x10-16 0.00 * 
Azithromycin 8mg/L-Asparagopsis 
armata          
38 <2x10-16 0.00 * 
Calliblepharis jubata-Asparagopsis 
armata       
38 <2x10-16 0.00 * 
Chloramphenicol 16mg/L-
Asparagopsis armata      
38 <2x10-16 1.00 - 
Chloramphenicol 8mg/L-
Asparagopsis armata       
38 <2x10-16 1.00 - 
Corallina officinalis-Asparagopsis 
armata       
38 <2x10-16 0.00 * 
Cystoseira baccata-Asparagopsis 
armata          
38 <2x10-16 1.00 - 
Fucus serratus-Asparagopsis 
armata              
38 <2x10-16 1.00 - 
Fucus vesiculosus-Asparagopsis 
armata           
38 <2x10-16 0.98 - 
Furcellaria lumbricalis-
Asparagopsis armata     
38 <2x10-16 0.00 * 
Gentamicin  16mg/L-Asparagopsis 
armata          
38 <2x10-16 0.00 * 
Gentamicin 2mg/L-Asparagopsis 
armata            
38 <2x10-16 0.00 * 
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Gentamicin 8mg/L-Asparagopsis 
armata            
38 <2x10-16 0.00 * 
Himanthalia elongata-Asparagopsis 
armata        
38 <2x10-16 0.43 - 
Polyides rotundus-Asparagopsis 
armata           
38 <2x10-16 0.00 * 
Sargassum muticum-Asparagopsis 
armata           
38 <2x10-16 0.03 * 
Ulva lactuca-Asparagopsis armata                38 <2x10-16 0.00 * 
Azithromycin 4mg/L-Azithromycin 
2mg/L           
38 <2x10-16 1.00 - 
Azithromycin 8mg/L-Azithromycin 
2mg/L           
38 <2x10-16 0.79 - 
Calliblepharis jubata-Azithromycin 
2mg/L        
38 <2x10-16 0.04 * 
Chloramphenicol 16mg/L-
Azithromycin 2mg/L       
38 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Azithromycin 2mg/L        
38 <2x10-16 0.00 * 
Corallina officinalis-Azithromycin 
2mg/L        
38 <2x10-16 1.00 - 
Cystoseira baccata-Azithromycin 
2mg/L           
38 <2x10-16 0.00 * 
Fucus serratus-Azithromycin 2mg/L               38 <2x10-16 0.00 * 
Fucus vesiculosus-Azithromycin 
2mg/L            
38 <2x10-16 0.00 * 
Furcellaria lumbricalis-Azithromycin 
2mg/L      
38 <2x10-16 1.00 - 
Gentamicin  16mg/L-Azithromycin 
2mg/L           
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Azithromycin 
2mg/L             
38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Azithromycin 
2mg/L             
38 <2x10-16 1.00 - 
Himanthalia elongata-Azithromycin 
2mg/L         
38 <2x10-16 0.00 * 
Polyides rotundus-Azithromycin 
2mg/L            
38 <2x10-16 0.09 - 
Sargassum muticum-Azithromycin 
2mg/L            
38 <2x10-16 0.00 * 
Ulva lactuca-Azithromycin 2mg/L                 38 <2x10-16 1.00 - 
Azithromycin 8mg/L-Azithromycin 
4mg/L           
38 <2x10-16 0.93 - 
Calliblepharis jubata-Azithromycin 
4mg/L        
38 <2x10-16 0.09 - 
Chloramphenicol 16mg/L-
Azithromycin 4mg/L       
38 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Azithromycin 4mg/L        
38 <2x10-16 0.00 * 
Corallina officinalis-Azithromycin 
4mg/L        
38 <2x10-16 1.00 - 
Cystoseira baccata-Azithromycin 
4mg/L           
38 <2x10-16 0.00 * 
Fucus serratus-Azithromycin 4mg/L               38 <2x10-16 0.00 * 
Fucus vesiculosus-Azithromycin 
4mg/L            
38 <2x10-16 0.00 * 
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Furcellaria lumbricalis-Azithromycin 
4mg/L      
38 <2x10-16 1.00 - 
Gentamicin  16mg/L-Azithromycin 
4mg/L           
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Azithromycin 
4mg/L             
38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Azithromycin 
4mg/L             
38 <2x10-16 1.00 - 
Himanthalia elongata-Azithromycin 
4mg/L         
38 <2x10-16 0.00 * 
Polyides rotundus-Azithromycin 
4mg/L            
38 <2x10-16 0.20 - 
Sargassum muticum-Azithromycin 
4mg/L            
38 <2x10-16 0.00 * 
Ulva lactuca-Azithromycin 4mg/L                 38 <2x10-16 1.00 - 
Calliblepharis jubata-Azithromycin 
8mg/L        
38 <2x10-16 1.00 - 
Chloramphenicol 16mg/L-
Azithromycin 8mg/L       
38 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Azithromycin 8mg/L        
38 <2x10-16 0.00 * 
Corallina officinalis-Azithromycin 
8mg/L        
38 <2x10-16 0.79 - 
Cystoseira baccata-Azithromycin 
8mg/L           
38 <2x10-16 0.00 * 
Fucus serratus-Azithromycin 8mg/L               38 <2x10-16 0.00 * 
Fucus vesiculosus-Azithromycin 
8mg/L            
38 <2x10-16 0.00 * 
Furcellaria lumbricalis-Azithromycin 
8mg/L      
38 <2x10-16 1.00 - 
Gentamicin  16mg/L-Azithromycin 
8mg/L           
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Azithromycin 
8mg/L             
38 <2x10-16 0.79 - 
Gentamicin 8mg/L-Azithromycin 
8mg/L             
38 <2x10-16 0.79 - 
Himanthalia elongata-Azithromycin 
8mg/L         
38 <2x10-16 0.00 * 
Polyides rotundus-Azithromycin 
8mg/L            
38 <2x10-16 1.00 - 
Sargassum muticum-Azithromycin 
8mg/L            
38 <2x10-16 0.00 * 
Ulva lactuca-Azithromycin 8mg/L                 38 <2x10-16 0.93 - 
Chloramphenicol 16mg/L-
Calliblepharis jubata    
38 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Calliblepharis jubata     
38 <2x10-16 0.00 * 
Corallina officinalis-Calliblepharis 
jubata     
38 <2x10-16 0.04 * 
Cystoseira baccata-Calliblepharis 
jubata        
38 <2x10-16 0.00 * 
Fucus serratus-Calliblepharis jubata            38 <2x10-16 0.00 * 
Fucus vesiculosus-Calliblepharis 
jubata         
38 <2x10-16 0.00 * 
Furcellaria lumbricalis-Calliblepharis 
jubata   
38 <2x10-16 0.82 - 
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Gentamicin  16mg/L-Calliblepharis 
jubata        
38 <2x10-16 0.67 - 
Gentamicin 2mg/L-Calliblepharis 
jubata          
38 <2x10-16 0.04 * 
Gentamicin 8mg/L-Calliblepharis 
jubata          
38 <2x10-16 0.04 * 
Himanthalia elongata-Calliblepharis 
jubata      
38 <2x10-16 0.00 * 
Polyides rotundus-Calliblepharis 
jubata         
38 <2x10-16 1.00 - 
Sargassum muticum-Calliblepharis 
jubata         
38 <2x10-16 0.00 * 
Ulva lactuca-Calliblepharis jubata              38 <2x10-16 0.09 - 
Chloramphenicol 8mg/L-
Chloramphenicol 16mg/L    
38 <2x10-16 1.00 - 
Corallina officinalis-
Chloramphenicol 16mg/L    
38 <2x10-16 0.00 * 
Cystoseira baccata-
Chloramphenicol 16mg/L       
38 <2x10-16 1.00 - 
Fucus serratus-Chloramphenicol 
16mg/L           
38 <2x10-16 1.00 - 
Fucus vesiculosus-Chloramphenicol 
16mg/L        
38 <2x10-16 0.90 - 
Furcellaria lumbricalis-
Chloramphenicol 16mg/L  
38 <2x10-16 0.00 * 
Gentamicin  16mg/L-
Chloramphenicol 16mg/L       
38 <2x10-16 0.00 * 
Gentamicin 2mg/L-Chloramphenicol 
16mg/L         
38 <2x10-16 0.00 * 
Gentamicin 8mg/L-Chloramphenicol 
16mg/L         
38 <2x10-16 0.00 * 
Himanthalia elongata-
Chloramphenicol 16mg/L     
38 <2x10-16 0.21 - 
Polyides rotundus-Chloramphenicol 
16mg/L        
38 <2x10-16 0.00 * 
Sargassum muticum-
Chloramphenicol 16mg/L        
38 <2x10-16 0.01 * 
Ulva lactuca-Chloramphenicol 
16mg/L             
38 <2x10-16 0.00 * 
Corallina officinalis-
Chloramphenicol 8mg/L     
38 <2x10-16 0.00 * 
Cystoseira baccata-
Chloramphenicol 8mg/L        
38 <2x10-16 1.00 - 
Fucus serratus-Chloramphenicol 
8mg/L            
38 <2x10-16 1.00 - 
Fucus vesiculosus-Chloramphenicol 
8mg/L         
38 <2x10-16 1.00 - 
Furcellaria lumbricalis-
Chloramphenicol 8mg/L   
38 <2x10-16 0.00 * 
Gentamicin  16mg/L-
Chloramphenicol 8mg/L        
38 <2x10-16 0.00 * 
Gentamicin 2mg/L-Chloramphenicol 
8mg/L          
38 <2x10-16 0.00 * 
Gentamicin 8mg/L-Chloramphenicol 
8mg/L          
38 <2x10-16 0.00 * 
Himanthalia elongata-
Chloramphenicol 8mg/L      
38 <2x10-16 0.69 - 
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Polyides rotundus-Chloramphenicol 
8mg/L         
38 <2x10-16 0.00 * 
Sargassum muticum-
Chloramphenicol 8mg/L         
38 <2x10-16 0.09 - 
Ulva lactuca-Chloramphenicol 
8mg/L              
38 <2x10-16 0.00 * 
Cystoseira baccata-Corallina 
officinalis        
38 <2x10-16 0.00 * 
Fucus serratus-Corallina officinalis            38 <2x10-16 0.00 * 
Fucus vesiculosus-Corallina 
officinalis         
38 <2x10-16 0.00 * 
Furcellaria lumbricalis-Corallina 
officinalis   
38 <2x10-16 1.00 - 
Gentamicin  16mg/L-Corallina 
officinalis        
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Corallina 
officinalis          
38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Corallina 
officinalis          
38 <2x10-16 1.00 - 
Himanthalia elongata-Corallina 
officinalis      
38 <2x10-16 0.00 * 
Polyides rotundus-Corallina 
officinalis         
38 <2x10-16 0.09 - 
Sargassum muticum-Corallina 
officinalis         
38 <2x10-16 0.00 * 
Ulva lactuca-Corallina officinalis              38 <2x10-16 1.00 - 
Fucus serratus-Cystoseira baccata               38 <2x10-16 1.00 - 
Fucus vesiculosus-Cystoseira 
baccata            
38 <2x10-16 1.00 - 
Furcellaria lumbricalis-Cystoseira 
baccata      
38 <2x10-16 0.00 * 
Gentamicin  16mg/L-Cystoseira 
baccata           
38 <2x10-16 0.00 * 
Gentamicin 2mg/L-Cystoseira 
baccata             
38 <2x10-16 0.00 * 
Gentamicin 8mg/L-Cystoseira 
baccata             
38 <2x10-16 0.00 * 
Himanthalia elongata-Cystoseira 
baccata         
38 <2x10-16 0.99 - 
Polyides rotundus-Cystoseira 
baccata            
38 <2x10-16 0.00 * 
Sargassum muticum-Cystoseira 
baccata            
38 <2x10-16 0.57 - 
Ulva lactuca-Cystoseira baccata                 38 <2x10-16 0.00 * 
Fucus vesiculosus-Fucus serratus                38 <2x10-16 1.00 - 
Furcellaria lumbricalis-Fucus 
serratus          
38 <2x10-16 0.00 * 
Gentamicin  16mg/L-Fucus serratus               38 <2x10-16 0.00 * 
Gentamicin 2mg/L-Fucus serratus                 38 <2x10-16 0.00 * 
Gentamicin 8mg/L-Fucus serratus                 38 <2x10-16 0.00 * 
Himanthalia elongata-Fucus 
serratus             
38 <2x10-16 0.65 - 
Polyides rotundus-Fucus serratus                38 <2x10-16 0.00 * 
Sargassum muticum-Fucus 
serratus                
38 <2x10-16 0.08 - 
Ulva lactuca-Fucus serratus                     38 <2x10-16 0.00 * 
82 
 
Furcellaria lumbricalis-Fucus 
vesiculosus       
38 <2x10-16 0.00 * 
Gentamicin  16mg/L-Fucus 
vesiculosus            
38 <2x10-16 0.00 * 
Gentamicin 2mg/L-Fucus 
vesiculosus              
38 <2x10-16 0.00 * 
Gentamicin 8mg/L-Fucus 
vesiculosus              
38 <2x10-16 0.00 * 
Himanthalia elongata-Fucus 
vesiculosus          
38 <2x10-16 1.00 - 
Polyides rotundus-Fucus 
vesiculosus             
38 <2x10-16 0.00 * 
Sargassum muticum-Fucus 
vesiculosus             
38 <2x10-16 0.92 - 
Ulva lactuca-Fucus vesiculosus                  38 <2x10-16 0.00 * 
Gentamicin  16mg/L-Furcellaria 
lumbricalis      
38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Furcellaria 
lumbricalis        
38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Furcellaria 
lumbricalis        
38 <2x10-16 1.00 - 
Himanthalia elongata-Furcellaria 
lumbricalis    
38 <2x10-16 0.00 * 
Polyides rotundus-Furcellaria 
lumbricalis       
38 <2x10-16 0.94 - 
Sargassum muticum-Furcellaria 
lumbricalis       
38 <2x10-16 0.00 * 
Ulva lactuca-Furcellaria lumbricalis            38 <2x10-16 1.00 - 
Gentamicin 2mg/L-Gentamicin  
16mg/L             
38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Gentamicin  
16mg/L             
38 <2x10-16 1.00 - 
Himanthalia elongata-Gentamicin  
16mg/L         
38 <2x10-16 0.00 * 
Polyides rotundus-Gentamicin  
16mg/L            
38 <2x10-16 0.86 - 
Sargassum muticum-Gentamicin  
16mg/L            
38 <2x10-16 0.00 * 
Ulva lactuca-Gentamicin  16mg/L                 38 <2x10-16 1.00 - 
Gentamicin 8mg/L-Gentamicin 
2mg/L               
38 <2x10-16 1.00 - 
Himanthalia elongata-Gentamicin 
2mg/L           
38 <2x10-16 0.00 * 
Polyides rotundus-Gentamicin 
2mg/L              
38 <2x10-16 0.09 - 
Sargassum muticum-Gentamicin 
2mg/L              
38 <2x10-16 0.00 * 
Ulva lactuca-Gentamicin 2mg/L                   38 <2x10-16 1.00 - 
Himanthalia elongata-Gentamicin 
8mg/L           
38 <2x10-16 0.00 * 
Polyides rotundus-Gentamicin 
8mg/L              
38 <2x10-16 0.09 - 
Sargassum muticum-Gentamicin 
8mg/L              
38 <2x10-16 0.00 * 
Ulva lactuca-Gentamicin 8mg/L                   38 <2x10-16 1.00 - 
Polyides rotundus-Himanthalia 
elongata          
38 <2x10-16 0.00 * 
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Sargassum muticum-Himanthalia 
elongata          
38 <2x10-16 1.00 - 
Ulva lactuca-Himanthalia elongata               38 <2x10-16 0.00 * 
Sargassum muticum-Polyides 
rotundus             
38 <2x10-16 0.00 * 
Ulva lactuca-Polyides rotundus                  38 <2x10-16 0.20 - 
Ulva lactuca-Sargassum muticum                  38 <2x10-16 0.00 * 
     
Figure 4B. Antimicrobial Agents effects on Yellow Vibrio 
Ampicillin 4mg/L-Ampicillin 16mg/L              27 <2x10-16 0.99 - 
Ampicillin 8mg/L-Ampicillin 16mg/L              27 <2x10-16 1.00 - 
Asparagopsis armata-Ampicillin 
16mg/L           
27 <2x10-16 0.00 * 
Azithromycin 2mg/L-Ampicillin 
16mg/L            
27 <2x10-16 1.00 - 
Azithromycin 4mg/L-Ampicillin 
16mg/L            
27 <2x10-16 1.00 - 
Azithromycin 8mg/L-Ampicillin 
16mg/L            
27 <2x10-16 0.94 - 
Calliblepharis jubata-Ampicillin 
16mg/L         
27 <2x10-16 1.00 - 
Chloramphenicol 16mg/L-Ampicillin 
16mg/L        
27 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-Ampicillin 
16mg/L         
27 <2x10-16 0.00 * 
Corallina officinalis-Ampicillin 
16mg/L         
27 <2x10-16 1.00 - 
Cystoseira baccata-Ampicillin 
16mg/L            
27 <2x10-16 0.00 * 
Fucus serratus-Ampicillin 16mg/L                27 <2x10-16 0.00 * 
Fucus vesiculosus-Ampicillin 
16mg/L             
27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Ampicillin 
16mg/L       
27 <2x10-16 1.00 - 
Gentamicin  16mg/L-Ampicillin 
16mg/L            
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Ampicillin 
16mg/L              
27 <2x10-16 0.99 - 
Gentamicin 8mg/L-Ampicillin 
16mg/L              
27 <2x10-16 1.00 - 
Himanthalia elongata-Ampicillin 
16mg/L          
27 <2x10-16 0.00 * 
Polyides rotundus-Ampicillin 
16mg/L             
27 <2x10-16 1.00 - 
Sargassum muticum-Ampicillin 
16mg/L             
27 <2x10-16 0.00 * 
Ulva lactuca-Ampicillin 16mg/L                  27 <2x10-16 1.00 - 
Ampicillin 8mg/L-Ampicillin 4mg/L               27 <2x10-16 1.00 - 
Asparagopsis armata-Ampicillin 
4mg/L            
27 <2x10-16 0.00 * 
Azithromycin 2mg/L-Ampicillin 
4mg/L             
27 <2x10-16 1.00 - 
Azithromycin 4mg/L-Ampicillin 
4mg/L             
27 <2x10-16 1.00 - 
Azithromycin 8mg/L-Ampicillin 
4mg/L             
27 <2x10-16 0.05 - 
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Calliblepharis jubata-Ampicillin 
4mg/L          
27 <2x10-16 0.42 - 
Chloramphenicol 16mg/L-Ampicillin 
4mg/L         
27 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-Ampicillin 
4mg/L          
27 <2x10-16 0.00 * 
Corallina officinalis-Ampicillin 4mg/L          27 <2x10-16 1.00 - 
Cystoseira baccata-Ampicillin 
4mg/L             
27 <2x10-16 0.00 * 
Fucus serratus-Ampicillin 4mg/L                 27 <2x10-16 0.00 * 
Fucus vesiculosus-Ampicillin 4mg/L              27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Ampicillin 
4mg/L        
27 <2x10-16 0.58 - 
Gentamicin  16mg/L-Ampicillin 
4mg/L             
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Ampicillin 4mg/L               27 <2x10-16 1.00 - 
Gentamicin 8mg/L-Ampicillin 4mg/L               27 <2x10-16 1.00 - 
Himanthalia elongata-Ampicillin 
4mg/L           
27 <2x10-16 0.00 * 
Polyides rotundus-Ampicillin 4mg/L              27 <2x10-16 0.67 - 
Sargassum muticum-Ampicillin 
4mg/L              
27 <2x10-16 0.00 * 
Ulva lactuca-Ampicillin 4mg/L                   27 <2x10-16 1.00 - 
Asparagopsis armata-Ampicillin 
8mg/L            
27 <2x10-16 0.00 * 
Azithromycin 2mg/L-Ampicillin 
8mg/L             
27 <2x10-16 1.00 - 
Azithromycin 4mg/L-Ampicillin 
8mg/L             
27 <2x10-16 1.00 - 
Azithromycin 8mg/L-Ampicillin 
8mg/L             
27 <2x10-16 0.44 - 
Calliblepharis jubata-Ampicillin 
8mg/L          
27 <2x10-16 0.96 - 
Chloramphenicol 16mg/L-Ampicillin 
8mg/L         
27 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-Ampicillin 
8mg/L          
27 <2x10-16 0.00 * 
Corallina officinalis-Ampicillin 8mg/L          27 <2x10-16 1.00 - 
Cystoseira baccata-Ampicillin 
8mg/L             
27 <2x10-16 0.00 * 
Fucus serratus-Ampicillin 8mg/L                 27 <2x10-16 0.00 * 
Fucus vesiculosus-Ampicillin 8mg/L              27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Ampicillin 
8mg/L        
27 <2x10-16 0.99 - 
Gentamicin  16mg/L-Ampicillin 
8mg/L             
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Ampicillin 8mg/L               27 <2x10-16 1.00 - 
Gentamicin 8mg/L-Ampicillin 8mg/L               27 <2x10-16 1.00 - 
Himanthalia elongata-Ampicillin 
8mg/L           
27 <2x10-16 0.00 * 
Polyides rotundus-Ampicillin 8mg/L              27 <2x10-16 0.99 - 
Sargassum muticum-Ampicillin 
8mg/L              
27 <2x10-16 0.00 * 
Ulva lactuca-Ampicillin 8mg/L                   27 <2x10-16 1.00 - 
Azithromycin 2mg/L-Asparagopsis 
armata          
27 <2x10-16 0.00 * 
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Azithromycin 4mg/L-Asparagopsis 
armata          
27 <2x10-16 0.00 * 
Azithromycin 8mg/L-Asparagopsis 
armata          
27 <2x10-16 0.00 * 
Calliblepharis jubata-Asparagopsis 
armata       
27 <2x10-16 0.00 * 
Chloramphenicol 16mg/L-
Asparagopsis armata      
27 <2x10-16 1.00 - 
Chloramphenicol 8mg/L-
Asparagopsis armata       
27 <2x10-16 1.00 - 
Corallina officinalis-Asparagopsis 
armata       
27 <2x10-16 0.00 * 
Cystoseira baccata-Asparagopsis 
armata          
27 <2x10-16 1.00 - 
Fucus serratus-Asparagopsis 
armata              
27 <2x10-16 1.00 - 
Fucus vesiculosus-Asparagopsis 
armata           
27 <2x10-16 1.00 - 
Furcellaria lumbricalis-
Asparagopsis armata     
27 <2x10-16 0.00 * 
Gentamicin  16mg/L-Asparagopsis 
armata          
27 <2x10-16 0.00 * 
Gentamicin 2mg/L-Asparagopsis 
armata            
27 <2x10-16 0.00 * 
Gentamicin 8mg/L-Asparagopsis 
armata            
27 <2x10-16 0.00 * 
Himanthalia elongata-Asparagopsis 
armata        
27 <2x10-16 1.00 - 
Polyides rotundus-Asparagopsis 
armata           
27 <2x10-16 0.00 * 
Sargassum muticum-Asparagopsis 
armata           
27 <2x10-16 0.40 - 
Ulva lactuca-Asparagopsis armata                27 <2x10-16 0.00 * 
Azithromycin 4mg/L-Azithromycin 
2mg/L           
27 <2x10-16 1.00 - 
Azithromycin 8mg/L-Azithromycin 
2mg/L           
27 <2x10-16 0.13 - 
Calliblepharis jubata-Azithromycin 
2mg/L        
27 <2x10-16 0.67 - 
Chloramphenicol 16mg/L-
Azithromycin 2mg/L       
27 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Azithromycin 2mg/L        
27 <2x10-16 0.00 * 
Corallina officinalis-Azithromycin 
2mg/L        
27 <2x10-16 1.00 - 
Cystoseira baccata-Azithromycin 
2mg/L           
27 <2x10-16 0.00 * 
Fucus serratus-Azithromycin 2mg/L               27 <2x10-16 0.00 * 
Fucus vesiculosus-Azithromycin 
2mg/L            
27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Azithromycin 
2mg/L      
27 <2x10-16 0.81 - 
Gentamicin  16mg/L-Azithromycin 
2mg/L           
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Azithromycin 
2mg/L             
27 <2x10-16 1.00 - 
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Gentamicin 8mg/L-Azithromycin 
2mg/L             
27 <2x10-16 1.00 - 
Himanthalia elongata-Azithromycin 
2mg/L         
27 <2x10-16 0.00 * 
Polyides rotundus-Azithromycin 
2mg/L            
27 <2x10-16 0.87 - 
Sargassum muticum-Azithromycin 
2mg/L            
27 <2x10-16 0.00 * 
Ulva lactuca-Azithromycin 2mg/L                 27 <2x10-16 1.00 - 
Azithromycin 8mg/L-Azithromycin 
4mg/L           
27 <2x10-16 0.16 - 
Calliblepharis jubata-Azithromycin 
4mg/L        
27 <2x10-16 0.73 - 
Chloramphenicol 16mg/L-
Azithromycin 4mg/L       
27 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Azithromycin 4mg/L        
27 <2x10-16 0.00 * 
Corallina officinalis-Azithromycin 
4mg/L        
27 <2x10-16 1.00 - 
Cystoseira baccata-Azithromycin 
4mg/L           
27 <2x10-16 0.00 * 
Fucus serratus-Azithromycin 4mg/L               27 <2x10-16 0.00 * 
Fucus vesiculosus-Azithromycin 
4mg/L            
27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Azithromycin 
4mg/L      
27 <2x10-16 0.86 - 
Gentamicin  16mg/L-Azithromycin 
4mg/L           
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Azithromycin 
4mg/L             
27 <2x10-16 1.00 - 
Gentamicin 8mg/L-Azithromycin 
4mg/L             
27 <2x10-16 1.00 - 
Himanthalia elongata-Azithromycin 
4mg/L         
27 <2x10-16 0.00 * 
Polyides rotundus-Azithromycin 
4mg/L            
27 <2x10-16 0.91 - 
Sargassum muticum-Azithromycin 
4mg/L            
27 <2x10-16 0.00 * 
Ulva lactuca-Azithromycin 4mg/L                 27 <2x10-16 1.00 - 
Calliblepharis jubata-Azithromycin 
8mg/L        
27 <2x10-16 1.00 - 
Chloramphenicol 16mg/L-
Azithromycin 8mg/L       
27 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Azithromycin 8mg/L        
27 <2x10-16 0.01 * 
Corallina officinalis-Azithromycin 
8mg/L        
27 <2x10-16 0.10 - 
Cystoseira baccata-Azithromycin 
8mg/L           
27 <2x10-16 0.00 * 
Fucus serratus-Azithromycin 8mg/L               27 <2x10-16 0.00 * 
Fucus vesiculosus-Azithromycin 
8mg/L            
27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Azithromycin 
8mg/L      
27 <2x10-16 1.00 - 
Gentamicin  16mg/L-Azithromycin 
8mg/L           
27 <2x10-16 0.83 - 
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Gentamicin 2mg/L-Azithromycin 
8mg/L             
27 <2x10-16 0.05 - 
Gentamicin 8mg/L-Azithromycin 
8mg/L             
27 <2x10-16 0.23 - 
Himanthalia elongata-Azithromycin 
8mg/L         
27 <2x10-16 0.01 * 
Polyides rotundus-Azithromycin 
8mg/L            
27 <2x10-16 1.00 - 
Sargassum muticum-Azithromycin 
8mg/L            
27 <2x10-16 0.49 - 
Ulva lactuca-Azithromycin 8mg/L                 27 <2x10-16 0.17 - 
Chloramphenicol 16mg/L-
Calliblepharis jubata    
27 <2x10-16 0.00 * 
Chloramphenicol 8mg/L-
Calliblepharis jubata     
27 <2x10-16 0.00 * 
Corallina officinalis-Calliblepharis 
jubata     
27 <2x10-16 0.60 - 
Cystoseira baccata-Calliblepharis 
jubata        
27 <2x10-16 0.00 * 
Fucus serratus-Calliblepharis jubata            27 <2x10-16 0.00 * 
Fucus vesiculosus-Calliblepharis 
jubata         
27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Calliblepharis 
jubata   
27 <2x10-16 1.00 - 
Gentamicin  16mg/L-Calliblepharis 
jubata        
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Calliblepharis 
jubata          
27 <2x10-16 0.42 - 
Gentamicin 8mg/L-Calliblepharis 
jubata          
27 <2x10-16 0.83 - 
Himanthalia elongata-Calliblepharis 
jubata      
27 <2x10-16 0.00 * 
Polyides rotundus-Calliblepharis 
jubata         
27 <2x10-16 1.00 - 
Sargassum muticum-Calliblepharis 
jubata         
27 <2x10-16 0.06 - 
Ulva lactuca-Calliblepharis jubata              27 <2x10-16 0.75 - 
Chloramphenicol 8mg/L-
Chloramphenicol 16mg/L    
27 <2x10-16 1.00 - 
Corallina officinalis-
Chloramphenicol 16mg/L    
27 <2x10-16 0.00 * 
Cystoseira baccata-
Chloramphenicol 16mg/L       
27 <2x10-16 1.00 - 
Fucus serratus-Chloramphenicol 
16mg/L           
27 <2x10-16 1.00 - 
Fucus vesiculosus-Chloramphenicol 
16mg/L        
27 <2x10-16 1.00 - 
Furcellaria lumbricalis-
Chloramphenicol 16mg/L  
27 <2x10-16 0.00 * 
Gentamicin  16mg/L-
Chloramphenicol 16mg/L       
27 <2x10-16 0.00 * 
Gentamicin 2mg/L-Chloramphenicol 
16mg/L         
27 <2x10-16 0.00 * 
Gentamicin 8mg/L-Chloramphenicol 
16mg/L         
27 <2x10-16 0.00 * 
Himanthalia elongata-
Chloramphenicol 16mg/L     
27 <2x10-16 1.00 - 
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Polyides rotundus-Chloramphenicol 
16mg/L        
27 <2x10-16 0.00 * 
Sargassum muticum-
Chloramphenicol 16mg/L        
27 <2x10-16 0.87 - 
Ulva lactuca-Chloramphenicol 
16mg/L             
27 <2x10-16 0.00 * 
Corallina officinalis-
Chloramphenicol 8mg/L     
27 <2x10-16 0.00 * 
Cystoseira baccata-
Chloramphenicol 8mg/L        
27 <2x10-16 0.98 - 
Fucus serratus-Chloramphenicol 
8mg/L            
27 <2x10-16 1.00 - 
Fucus vesiculosus-Chloramphenicol 
8mg/L         
27 <2x10-16 1.00 - 
Furcellaria lumbricalis-
Chloramphenicol 8mg/L   
27 <2x10-16 0.00 * 
Gentamicin  16mg/L-
Chloramphenicol 8mg/L        
27 <2x10-16 0.00 * 
Gentamicin 2mg/L-Chloramphenicol 
8mg/L          
27 <2x10-16 0.00 * 
Gentamicin 8mg/L-Chloramphenicol 
8mg/L          
27 <2x10-16 0.00 * 
Himanthalia elongata-
Chloramphenicol 8mg/L      
27 <2x10-16 1.00 - 
Polyides rotundus-Chloramphenicol 
8mg/L         
27 <2x10-16 0.00 * 
Sargassum muticum-
Chloramphenicol 8mg/L         
27 <2x10-16 1.00 - 
Ulva lactuca-Chloramphenicol 
8mg/L              
27 <2x10-16 0.00 * 
Cystoseira baccata-Corallina 
officinalis        
27 <2x10-16 0.00 * 
Fucus serratus-Corallina officinalis            27 <2x10-16 0.00 * 
Fucus vesiculosus-Corallina 
officinalis         
27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Corallina 
officinalis   
27 <2x10-16 0.75 - 
Gentamicin  16mg/L-Corallina 
officinalis        
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Corallina 
officinalis          
27 <2x10-16 1.00 - 
Gentamicin 8mg/L-Corallina 
officinalis          
27 <2x10-16 1.00 - 
Himanthalia elongata-Corallina 
officinalis      
27 <2x10-16 0.00 * 
Polyides rotundus-Corallina 
officinalis         
27 <2x10-16 0.83 - 
Sargassum muticum-Corallina 
officinalis         
27 <2x10-16 0.00 * 
Ulva lactuca-Corallina officinalis              27 <2x10-16 1.00 - 
Fucus serratus-Cystoseira baccata               27 <2x10-16 1.00 - 
Fucus vesiculosus-Cystoseira 
baccata            
27 <2x10-16 1.00 - 
Furcellaria lumbricalis-Cystoseira 
baccata      
27 <2x10-16 0.00 * 
Gentamicin  16mg/L-Cystoseira 
baccata           
27 <2x10-16 0.00 * 
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Gentamicin 2mg/L-Cystoseira 
baccata             
27 <2x10-16 0.00 * 
Gentamicin 8mg/L-Cystoseira 
baccata             
27 <2x10-16 0.00 * 
Himanthalia elongata-Cystoseira 
baccata         
27 <2x10-16 0.98 - 
Polyides rotundus-Cystoseira 
baccata            
27 <2x10-16 0.00 * 
Sargassum muticum-Cystoseira 
baccata            
27 <2x10-16 0.16 - 
Ulva lactuca-Cystoseira baccata                 27 <2x10-16 0.00 * 
Fucus vesiculosus-Fucus serratus                27 <2x10-16 1.00 - 
Furcellaria lumbricalis-Fucus 
serratus          
27 <2x10-16 0.00 * 
Gentamicin  16mg/L-Fucus serratus               27 <2x10-16 0.00 * 
Gentamicin 2mg/L-Fucus serratus                 27 <2x10-16 0.00 * 
Gentamicin 8mg/L-Fucus serratus                 27 <2x10-16 0.00 * 
Himanthalia elongata-Fucus 
serratus             
27 <2x10-16 1.00 - 
Polyides rotundus-Fucus serratus                27 <2x10-16 0.00 * 
Sargassum muticum-Fucus 
serratus                
27 <2x10-16 0.53 - 
Ulva lactuca-Fucus serratus                     27 <2x10-16 0.00 * 
Furcellaria lumbricalis-Fucus 
vesiculosus       
27 <2x10-16 0.00 * 
Gentamicin  16mg/L-Fucus 
vesiculosus            
27 <2x10-16 0.00 * 
Gentamicin 2mg/L-Fucus 
vesiculosus              
27 <2x10-16 0.00 * 
Gentamicin 8mg/L-Fucus 
vesiculosus              
27 <2x10-16 0.00 * 
Himanthalia elongata-Fucus 
vesiculosus          
27 <2x10-16 1.00 - 
Polyides rotundus-Fucus 
vesiculosus             
27 <2x10-16 0.00 * 
Sargassum muticum-Fucus 
vesiculosus             
27 <2x10-16 0.46 - 
Ulva lactuca-Fucus vesiculosus                  27 <2x10-16 0.00 * 
Gentamicin  16mg/L-Furcellaria 
lumbricalis      
27 <2x10-16 1.00 - 
Gentamicin 2mg/L-Furcellaria 
lumbricalis        
27 <2x10-16 0.58 - 
Gentamicin 8mg/L-Furcellaria 
lumbricalis        
27 <2x10-16 0.92 - 
Himanthalia elongata-Furcellaria 
lumbricalis    
27 <2x10-16 0.00 * 
Polyides rotundus-Furcellaria 
lumbricalis       
27 <2x10-16 1.00 - 
Sargassum muticum-Furcellaria 
lumbricalis       
27 <2x10-16 0.03 * 
Ulva lactuca-Furcellaria lumbricalis            27 <2x10-16 0.87 - 
Gentamicin 2mg/L-Gentamicin  
16mg/L             
27 <2x10-16 1.00 - 
Gentamicin 8mg/L-Gentamicin  
16mg/L             
27 <2x10-16 1.00 - 
90 
 
Himanthalia elongata-Gentamicin  
16mg/L         
27 <2x10-16 0.00 * 
Polyides rotundus-Gentamicin  
16mg/L            
27 <2x10-16 1.00 - 
Sargassum muticum-Gentamicin  
16mg/L            
27 <2x10-16 0.00 * 
Ulva lactuca-Gentamicin  16mg/L                 27 <2x10-16 1.00 - 
Gentamicin 8mg/L-Gentamicin 
2mg/L               
27 <2x10-16 1.00 - 
Himanthalia elongata-Gentamicin 
2mg/L           
27 <2x10-16 0.00 * 
Polyides rotundus-Gentamicin 
2mg/L              
27 <2x10-16 0.67 - 
Sargassum muticum-Gentamicin 
2mg/L              
27 <2x10-16 0.00 * 
Ulva lactuca-Gentamicin 2mg/L                   27 <2x10-16 1.00 - 
Himanthalia elongata-Gentamicin 
8mg/L           
27 <2x10-16 0.00 * 
Polyides rotundus-Gentamicin 
8mg/L              
27 <2x10-16 0.96 - 
Sargassum muticum-Gentamicin 
8mg/L              
27 <2x10-16 0.00 * 
Ulva lactuca-Gentamicin 8mg/L                   27 <2x10-16 1.00 - 
Polyides rotundus-Himanthalia 
elongata          
27 <2x10-16 0.00 * 
Sargassum muticum-Himanthalia 
elongata          
27 <2x10-16 1.00 - 
Ulva lactuca-Himanthalia elongata               27 <2x10-16 0.00 * 
Sargassum muticum-Polyides 
rotundus             
27 <2x10-16 0.02 * 
Ulva lactuca-Polyides rotundus                  27 <2x10-16 0.92 - 
Ulva lactuca-Sargassum muticum                  27 <2x10-16 0.00 * 
     
Figure 5. Antimicrobial Agents effects on S. aureus 
Chloramphenicol 20-
Chloramphenicol 10  
3 <2x10-16 0.00 * 
Chloramphenicol 5-
Chloramphenicol 10   
3 <2x10-16 0.06 - 
Erythromycin 10-Chloramphenicol 
10     
3 <2x10-16 0.00 * 
Erythromycin 2.5-Chloramphenicol 
10    
3 <2x10-16 0.00 * 
Erythromycin 5-Chloramphenicol 10      3 <2x10-16 0.00 * 
Fucoxanthin 1600-Chloramphenicol 
10    
3 <2x10-16 0.06 - 
Fucoxanthin 800-Chloramphenicol 
10     
3 <2x10-16 0.06 - 
Kanamycin 100-Chloramphenicol 
10       
3 <2x10-16 0.00 * 
Kanamycin 25-Chloramphenicol 10        3 <2x10-16 0.00 * 
Kanamycin 50-Chloramphenicol 10        3 <2x10-16 0.00 * 
Tetracycline 10-Chloramphenicol 10     3 <2x10-16 0.00 * 
Tetracycline 2.5-Chloramphenicol 
10    
3 <2x10-16 0.00 * 
Tetracycline 5-Chloramphenicol 10      3 <2x10-16 0.00 * 
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Chloramphenicol 5-
Chloramphenicol 20   
3 <2x10-16 0.00 * 
Erythromycin 10-Chloramphenicol 
20     
3 <2x10-16 1.00 - 
Erythromycin 2.5-Chloramphenicol 
20    
3 <2x10-16 0.53 - 
Erythromycin 5-Chloramphenicol 20      3 <2x10-16 1.00 - 
Fucoxanthin 1600-Chloramphenicol 
20    
3 <2x10-16 0.00 * 
Fucoxanthin 800-Chloramphenicol 
20     
3 <2x10-16 0.00 * 
Kanamycin 100-Chloramphenicol 
20       
3 <2x10-16 0.00 * 
Kanamycin 25-Chloramphenicol 20        3 <2x10-16 0.00 * 
Kanamycin 50-Chloramphenicol 20        3 <2x10-16 0.00 * 
Tetracycline 10-Chloramphenicol 20     3 <2x10-16 0.00 * 
Tetracycline 2.5-Chloramphenicol 20    3 <2x10-16 0.00 * 
Tetracycline 5-Chloramphenicol 20      3 <2x10-16 0.00 * 
Erythromycin 10-Chloramphenicol 5      3 <2x10-16 0.00 * 
Erythromycin 2.5-Chloramphenicol 5     3 <2x10-16 0.00 * 
Erythromycin 5-Chloramphenicol 5       3 <2x10-16 0.00 * 
Fucoxanthin 1600-Chloramphenicol 5     3 <2x10-16 1.00 - 
Fucoxanthin 800-Chloramphenicol 5      3 <2x10-16 1.00 - 
Kanamycin 100-Chloramphenicol 5        3 <2x10-16 0.00 * 
Kanamycin 25-Chloramphenicol 5         3 <2x10-16 0.00 * 
Kanamycin 50-Chloramphenicol 5         3 <2x10-16 0.00 * 
Tetracycline 10-Chloramphenicol 5      3 <2x10-16 0.00 * 
Tetracycline 2.5-Chloramphenicol 5     3 <2x10-16 0.00 * 
Tetracycline 5-Chloramphenicol 5       3 <2x10-16 0.00 * 
Erythromycin 2.5-Erythromycin 10       3 <2x10-16 0.53 - 
Erythromycin 5-Erythromycin 10         3 <2x10-16 1.00 - 
Fucoxanthin 1600-Erythromycin 10       3 <2x10-16 0.00 * 
Fucoxanthin 800-Erythromycin 10        3 <2x10-16 0.00 * 
Kanamycin 100-Erythromycin 10          3 <2x10-16 0.00 * 
Kanamycin 25-Erythromycin 10           3 <2x10-16 0.00 * 
Kanamycin 50-Erythromycin 10           3 <2x10-16 0.00 * 
Tetracycline 10-Erythromycin 10        3 <2x10-16 0.00 * 
Tetracycline 2.5-Erythromycin 10       3 <2x10-16 0.00 * 
Tetracycline 5-Erythromycin 10         3 <2x10-16 0.00 * 
Erythromycin 5-Erythromycin 2.5        3 <2x10-16 0.53 - 
Fucoxanthin 1600-Erythromycin 2.5      3 <2x10-16 0.00 * 
Fucoxanthin 800-Erythromycin 2.5       3 <2x10-16 0.00 * 
Kanamycin 100-Erythromycin 2.5         3 <2x10-16 0.00 * 
Kanamycin 25-Erythromycin 2.5          3 <2x10-16 0.00 * 
Kanamycin 50-Erythromycin 2.5          3 <2x10-16 0.00 * 
Tetracycline 10-Erythromycin 2.5       3 <2x10-16 0.00 * 
Tetracycline 2.5-Erythromycin 2.5      3 <2x10-16 0.00 * 
Tetracycline 5-Erythromycin 2.5        3 <2x10-16 0.00 * 
Fucoxanthin 1600-Erythromycin 5        3 <2x10-16 0.00 * 
Fucoxanthin 800-Erythromycin 5         3 <2x10-16 0.00 * 
Kanamycin 100-Erythromycin 5           3 <2x10-16 0.00 * 
Kanamycin 25-Erythromycin 5            3 <2x10-16 0.00 * 
Kanamycin 50-Erythromycin 5            3 <2x10-16 0.00 * 
Tetracycline 10-Erythromycin 5         3 <2x10-16 0.00 * 
Tetracycline 2.5-Erythromycin 5        3 <2x10-16 0.00 * 
Tetracycline 5-Erythromycin 5          3 <2x10-16 0.00 * 
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Fucoxanthin 800-Fucoxanthin 1600       3 <2x10-16 1.00 - 
Kanamycin 100-Fucoxanthin 1600         3 <2x10-16 0.00 * 
Kanamycin 25-Fucoxanthin 1600          3 <2x10-16 0.00 * 
Kanamycin 50-Fucoxanthin 1600          3 <2x10-16 0.00 * 
Tetracycline 10-Fucoxanthin 1600       3 <2x10-16 0.00 * 
Tetracycline 2.5-Fucoxanthin 1600      3 <2x10-16 0.00 * 
Tetracycline 5-Fucoxanthin 1600        3 <2x10-16 0.00 * 
Kanamycin 100-Fucoxanthin 800          3 <2x10-16 0.00 * 
Kanamycin 25-Fucoxanthin 800           3 <2x10-16 0.00 * 
Kanamycin 50-Fucoxanthin 800           3 <2x10-16 0.00 * 
Tetracycline 10-Fucoxanthin 800        3 <2x10-16 0.00 * 
Tetracycline 2.5-Fucoxanthin 800       3 <2x10-16 0.00 * 
Tetracycline 5-Fucoxanthin 800         3 <2x10-16 0.00 * 
Kanamycin 25-Kanamycin 100             3 <2x10-16 1.00 - 
Kanamycin 50-Kanamycin 100             3 <2x10-16 1.00 - 
Tetracycline 10-Kanamycin 100          3 <2x10-16 0.06 - 
Tetracycline 2.5-Kanamycin 100         3 <2x10-16 0.00 * 
Tetracycline 5-Kanamycin 100           3 <2x10-16 0.00 * 
Kanamycin 50-Kanamycin 25              3 <2x10-16 1.00 - 
Tetracycline 10-Kanamycin 25           3 <2x10-16 0.06 - 
Tetracycline 2.5-Kanamycin 25          3 <2x10-16 0.00 * 
Tetracycline 5-Kanamycin 25            3 <2x10-16 0.00 * 
Tetracycline 10-Kanamycin 50           3 <2x10-16 0.06 - 
Tetracycline 2.5-Kanamycin 50          3 <2x10-16 0.00 * 
Tetracycline 5-Kanamycin 50            3 <2x10-16 0.00 * 
Tetracycline 2.5-Tetracycline 10       3 <2x10-16 0.00 * 
Tetracycline 5-Tetracycline 10         3 <2x10-16 0.00 * 
Tetracycline 5-Tetracycline 2.5        3 <2x10-16 0.00 * 
Chloramphenicol 20-Chloramphenicol 10  3 <2x10-16 0.00 * 
Chloramphenicol 5-Chloramphenicol 10   3 <2x10-16 0.06 - 
Erythromycin 10-Chloramphenicol 10     3 <2x10-16 0.00 * 
Erythromycin 2.5-Chloramphenicol 10    3 <2x10-16 0.00 * 
Erythromycin 5-Chloramphenicol 10      3 <2x10-16 0.00 * 
Fucoxanthin 1600-Chloramphenicol 10    3 <2x10-16 0.06 - 
Fucoxanthin 800-Chloramphenicol 10     3 <2x10-16 0.06 - 
Kanamycin 100-Chloramphenicol 10       3 <2x10-16 0.00 * 
Kanamycin 25-Chloramphenicol 10        3 <2x10-16 0.00 * 
Kanamycin 50-Chloramphenicol 10        3 <2x10-16 0.00 * 
Tetracycline 10-Chloramphenicol 10     3 <2x10-16 0.00 * 
Tetracycline 2.5-Chloramphenicol 10    3 <2x10-16 0.00 * 
Tetracycline 5-Chloramphenicol 10      3 <2x10-16 0.00 * 
Chloramphenicol 5-Chloramphenicol 20   3 <2x10-16 0.00 * 
Erythromycin 10-Chloramphenicol 20     3 <2x10-16 1.00 - 
Erythromycin 2.5-Chloramphenicol 20    3 <2x10-16 0.53 - 
Erythromycin 5-Chloramphenicol 20      3 <2x10-16 1.00 - 
Fucoxanthin 1600-Chloramphenicol 20    3 <2x10-16 0.00 * 
Fucoxanthin 800-Chloramphenicol 20     3 <2x10-16 0.00 * 
Kanamycin 100-Chloramphenicol 20       3 <2x10-16 0.00 * 
Kanamycin 25-Chloramphenicol 20        3 <2x10-16 0.00 * 
Kanamycin 50-Chloramphenicol 20        3 <2x10-16 0.00 * 
Tetracycline 10-Chloramphenicol 20     3 <2x10-16 0.00 * 
Tetracycline 2.5-Chloramphenicol 20    3 <2x10-16 0.00 * 
Tetracycline 5-Chloramphenicol 20      3 <2x10-16 0.00 * 
Erythromycin 10-Chloramphenicol 5      3 <2x10-16 0.00 * 
Erythromycin 2.5-Chloramphenicol 5     3 <2x10-16 0.00 * 
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Erythromycin 5-Chloramphenicol 5       3 <2x10-16 0.00 * 
Fucoxanthin 1600-Chloramphenicol 5     3 <2x10-16 1.00 - 
Fucoxanthin 800-Chloramphenicol 5      3 <2x10-16 1.00 - 
Kanamycin 100-Chloramphenicol 5        3 <2x10-16 0.00 * 
Kanamycin 25-Chloramphenicol 5         3 <2x10-16 0.00 * 
Kanamycin 50-Chloramphenicol 5         3 <2x10-16 0.00 * 
Tetracycline 10-Chloramphenicol 5      3 <2x10-16 0.00 * 
Tetracycline 2.5-Chloramphenicol 5     3 <2x10-16 0.00 * 
Tetracycline 5-Chloramphenicol 5       3 <2x10-16 0.00 * 
Erythromycin 2.5-Erythromycin 10       3 <2x10-16 0.53 - 
Erythromycin 5-Erythromycin 10         3 <2x10-16 1.00 - 
Fucoxanthin 1600-Erythromycin 10       3 <2x10-16 0.00 * 
Fucoxanthin 800-Erythromycin 10        3 <2x10-16 0.00 * 
Kanamycin 100-Erythromycin 10          3 <2x10-16 0.00 * 
Kanamycin 25-Erythromycin 10           3 <2x10-16 0.00 * 
Kanamycin 50-Erythromycin 10           3 <2x10-16 0.00 * 
Tetracycline 10-Erythromycin 10        3 <2x10-16 0.00 * 
Tetracycline 2.5-Erythromycin 10       3 <2x10-16 0.00 * 
Tetracycline 5-Erythromycin 10         3 <2x10-16 0.00 * 
Erythromycin 5-Erythromycin 2.5        3 <2x10-16 0.53 - 
Fucoxanthin 1600-Erythromycin 2.5      3 <2x10-16 0.00 * 
Fucoxanthin 800-Erythromycin 2.5       3 <2x10-16 0.00 * 
Kanamycin 100-Erythromycin 2.5         3 <2x10-16 0.00 * 
Kanamycin 25-Erythromycin 2.5          3 <2x10-16 0.00 * 
Kanamycin 50-Erythromycin 2.5          3 <2x10-16 0.00 * 
Tetracycline 10-Erythromycin 2.5       3 <2x10-16 0.00 * 
Tetracycline 2.5-Erythromycin 2.5      3 <2x10-16 0.00 * 
Tetracycline 5-Erythromycin 2.5        3 <2x10-16 0.00 * 
Fucoxanthin 1600-Erythromycin 5        3 <2x10-16 0.00 * 
Fucoxanthin 800-Erythromycin 5         3 <2x10-16 0.00 * 
Kanamycin 100-Erythromycin 5           3 <2x10-16 0.00 * 
Kanamycin 25-Erythromycin 5            3 <2x10-16 0.00 * 
Kanamycin 50-Erythromycin 5            3 <2x10-16 0.00 * 
Tetracycline 10-Erythromycin 5         3 <2x10-16 0.00 * 
Tetracycline 2.5-Erythromycin 5        3 <2x10-16 0.00 * 
Tetracycline 5-Erythromycin 5          3 <2x10-16 0.00 * 
Fucoxanthin 800-Fucoxanthin 1600       3 <2x10-16 1.00 - 
Kanamycin 100-Fucoxanthin 1600         3 <2x10-16 0.00 * 
Kanamycin 25-Fucoxanthin 1600          3 <2x10-16 0.00 * 
Kanamycin 50-Fucoxanthin 1600          3 <2x10-16 0.00 * 
Tetracycline 10-Fucoxanthin 1600       3 <2x10-16 0.00 * 
Tetracycline 2.5-Fucoxanthin 1600      3 <2x10-16 0.00 * 
Tetracycline 5-Fucoxanthin 1600        3 <2x10-16 0.00 * 
Kanamycin 100-Fucoxanthin 800          3 <2x10-16 0.00 * 
Kanamycin 25-Fucoxanthin 800           3 <2x10-16 0.00 * 
Kanamycin 50-Fucoxanthin 800           3 <2x10-16 0.00 * 
Tetracycline 10-Fucoxanthin 800        3 <2x10-16 0.00 * 
Tetracycline 2.5-Fucoxanthin 800       3 <2x10-16 0.00 * 
Tetracycline 5-Fucoxanthin 800         3 <2x10-16 0.00 * 
Kanamycin 25-Kanamycin 100             3 <2x10-16 1.00 - 
Kanamycin 50-Kanamycin 100             3 <2x10-16 1.00 - 
Tetracycline 10-Kanamycin 100          3 <2x10-16 0.06 - 
Tetracycline 2.5-Kanamycin 100         3 <2x10-16 0.00 * 
Tetracycline 5-Kanamycin 100           3 <2x10-16 0.00 * 
Kanamycin 50-Kanamycin 25              3 <2x10-16 1.00 - 
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Tetracycline 10-Kanamycin 25           3 <2x10-16 0.06 - 
Tetracycline 2.5-Kanamycin 25          3 <2x10-16 0.00 * 
Tetracycline 5-Kanamycin 25            3 <2x10-16 0.00 * 
Tetracycline 10-Kanamycin 50           3 <2x10-16 0.06 - 
Tetracycline 2.5-Kanamycin 50          3 <2x10-16 0.00 * 
Tetracycline 5-Kanamycin 50            3 <2x10-16 0.00 * 
Tetracycline 2.5-Tetracycline 10       3 <2x10-16 0.00 * 
Tetracycline 5-Tetracycline 10         3 <2x10-16 0.00 * 
Tetracycline 5-Tetracycline 2.5        3 <2x10-16 0.00 * 
     
Figure 6A. Antibiotic Resistant Bacteria Isolated from Corallina officinalis 
Chorlamphenicol 2-Ampicillin 2    6 2.48E-08 0.31 - 
Ciprofloxacin 2-Ampicillin 2      6 2.48E-08 0.39 - 
Gentamicin 16-Ampicillin 2        6 2.48E-08 1.00 - 
Tetracycline 24-Ampicillin 2      6 2.48E-08 0.00 * 
Ciprofloxacin 2-Chorlamphenicol 2 6 2.48E-08 1.00 - 
Gentamicin 16-Chorlamphenicol 2   6 2.48E-08 0.34 - 
Tetracycline 24-Chorlamphenicol 2 6 2.48E-08 0.00 * 
Gentamicin 16-Ciprofloxacin 2     6 2.48E-08 0.42 - 
Tetracycline 24-Ciprofloxacin 2   6 2.48E-08 0.00 * 
Tetracycline 24-Gentamicin 16     6 2.48E-08 0.00 * 
     
Figure 6B. Antibiotic Resistant Bacteria Isolated from Furcellaria lumbricalis 
Chorlamphenicol 2-Ampicillin 2    6 1.83E-11 0.00 * 
Ciprofloxacin 2-Ampicillin 2      6 1.83E-11 0.00 * 
Gentamicin 16-Ampicillin 2        6 1.83E-11 1.00 - 
Tetracycline 24-Ampicillin 2      6 1.83E-11 0.00 * 
Ciprofloxacin 2-Chorlamphenicol 2 6 1.83E-11 1.00 - 
Gentamicin 16-Chorlamphenicol 2   6 1.83E-11 0.00 * 
Tetracycline 24-Chorlamphenicol 2 6 1.83E-11 0.00 * 
Gentamicin 16-Ciprofloxacin 2     6 1.83E-11 0.00 * 
Tetracycline 24-Ciprofloxacin 2   6 1.83E-11 0.00 * 
Tetracycline 24-Gentamicin 16     6 1.83E-11 0.00 * 
     
Figure 6C. Antibiotic Resistant Bacteria Isolated from Ulva lactuca 
Chorlamphenicol 2-Ampicillin 2    6 1.33E-05 0.03 * 
Ciprofloxacin 2-Ampicillin 2      6 1.33E-05 0.05 - 
Gentamicin 16-Ampicillin 2        6 1.33E-05 0.14 - 
Tetracycline 24-Ampicillin 2      6 1.33E-05 0.10 - 
Ciprofloxacin 2-Chorlamphenicol 2 6 1.33E-05 1.00 - 
Gentamicin 16-Chorlamphenicol 2   6 1.33E-05 0.96 - 
Tetracycline 24-Chorlamphenicol 2 6 1.33E-05 0.00  
Gentamicin 16-Ciprofloxacin 2     6 1.33E-05 0.99 - 
Tetracycline 24-Ciprofloxacin 2   6 1.33E-05 0.00 * 
Tetracycline 24-Gentamicin 16     6 1.33E-05 0.00 * 
     
Figure 6. Resistance to Ampicillin (2mg/L) 
Furcellaria lumbricalis-Corallina officinalis 6 0.01 0.94 - 
Ulva lactuca-Corallina officinalis   6 0.01 0.01 * 
Ulva lactuca-Furcellaria lumbricalis 6 0.01 0.03 * 
     
Figure 6. Resistance to Chloramphenicol (2 mg/L) 
N/A 6 0.09 N/A N/A 
     
Figure 6. Resistance to Ciprofloxacin (2 mg/L) 
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N/A 6 0.30 N/A N/A 
     
Figure 6. Resistance to Gentamicin (16 mg/L) 
N/A 6 0.30 N/A N/A 
     
Figure 6. Resistance to Tetracycline (24 mg/L) 
Furcellaria lumbricalis-Corallina officinalis 6 0.04 0.64 - 
Ulva lactuca-Corallina officinalis 6 0.04 0.18 - 
Ulva lactuca-Furcellaria lumbricalis 6 0.04 0.03 * 
     
Figure 7. Prevalence of intI1 Species Comparison 
Control-Asparagopsis armata                   3 0.01 1.00 - 
Corallina officinalis-Asparagopsis armata     3 0.01 1.00 - 
Fucus serratus-Asparagopsis armata            3 0.01 0.05 - 
Fucus Vesiculosus -Asparagopsis armata        3 0.01 0.02 * 
Furcellaria lumbricalis-Asparagopsis armata   3 0.01 0.27 - 
Ulva lactuca-Asparagopsis armata              3 0.01 1.00 - 
Corallina officinalis-Control                 3 0.01 1.00 - 
Fucus serratus-Control                        3 0.01 0.39 - 
Fucus Vesiculosus -Control                    3 0.01 0.24 - 
Furcellaria lumbricalis-Control               3 0.01 0.76 - 
Ulva lactuca-Control                          3 0.01 1.00 - 
Fucus serratus-Corallina officinalis          3 0.01 0.11 - 
Fucus Vesiculosus -Corallina officinalis      3 0.01 0.05 - 
Furcellaria lumbricalis-Corallina officinalis 3 0.01 0.46 - 
Ulva lactuca-Corallina officinalis            3 0.01 1.00 - 
Fucus Vesiculosus -Fucus serratus             3 0.01 1.00 - 
Furcellaria lumbricalis-Fucus serratus        3 0.01 0.99 - 
Ulva lactuca-Fucus serratus                   3 0.01 0.08 - 
Furcellaria lumbricalis-Fucus Vesiculosus     3 0.01 0.87 - 
Ulva lactuca-Fucus Vesiculosus                3 0.01 0.03 * 
Ulva lactuca-Furcellaria lumbricalis          3 0.01 0.37 - 
     
Figure 8. Prevalence of intI1 Site Comparison 
Control (GB)-Control (CB)                     3 1.41E-07 0.00 * 
Fucus serratus (CB)-Control (CB)              3 1.41E-07 0.56 - 
Fucus serratus (GB)-Control (CB)              3 1.41E-07 0.37 - 
Fucus Vesiculosus (CB)-Control (CB)           3 1.41E-07 0.41 - 
Fucus Vesiculosus (GB)-Control (CB)           3 1.41E-07 0.20 - 
Fucus serratus (CB)-Control (GB)              3 1.41E-07 0.00 * 
Fucus serratus (GB)-Control (GB)              3 1.41E-07 0.00 * 
Fucus Vesiculosus (CB)-Control (GB)           3 1.41E-07 0.00 * 
Fucus Vesiculosus (GB)-Control (GB)           3 1.41E-07 0.00 * 
Fucus serratus (GB)-Fucus serratus (CB)       3 1.41E-07 0.99 - 
Fucus Vesiculosus (CB)-Fucus serratus (CB)    3 1.41E-07 1.00 - 
Fucus Vesiculosus (GB)-Fucus serratus (CB)    3 1.41E-07 0.79 - 
Fucus Vesiculosus (CB)-Fucus serratus (GB)    3 1.41E-07 1.00 - 
Fucus Vesiculosus (GB)-Fucus serratus (GB)    3 1.41E-07 0.97 - 
Fucus Vesiculosus (GB)-Fucus Vesiculosus (CB) 3 1.41E-07 0.95 - 
     
Figure 11. Abundance of ARG’s 
Corallina officinalis-Asparagopsis armata     3 0.04 0.18 - 
Furcellaria lumbricalis-Asparagopsis armata   3 0.04 0.03 * 
Ulva lactuca-Asparagopsis armata              3 0.04 0.46 - 
Furcellaria lumbricalis-Corallina officinalis 3 0.04 0.54 - 
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Ulva lactuca-Corallina officinalis            3 0.04 0.88 - 
Ulva lactuca-Furcellaria lumbricalis          3 0.04 0.22 - 
     
Figure 12. Diversity of ARG’s 
N/A 3 1.00 N/A N/A 
 
 
 
Figure S1 
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PCR plate visualising the expression of IntI1 and 16s genes in bacteria isolated from: A: Ulva lactuca 
B: Fucus vesiculosus C: Fucus serratus D: Himanthalia elongate and E: Cystoseira baccata.   
 
 
 
 
 
 
 
 
 
 
 
Figure S2 
Breakdown of the bacteria isolated from sample two (Asparagopsis armata) samples ranging from 
phylum to species. 
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Figure S3 
Breakdown of the bacteria isolated from sample three (Asparagopsis armata) samples ranging from 
phylum to species. 
 
 
 
 
 
 
 
 
 
Figure S4 
Breakdown of the bacteria isolated from sample four (Corallina officinalis) samples ranging from 
phylum to species. 
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Figure S5 
Breakdown of the bacteria isolated from sample five (Corallina officinalis) samples ranging from 
phylum to species. 
 
 
 
 
 
 
 
 
 
Figure S6 
Breakdown of the bacteria isolated from sample six (Corallina officinalis) samples ranging from 
phylum to species. 
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Figure S7 
Breakdown of the bacteria isolated from sample seven (Ulva lactuca) samples ranging from phylum 
to species. 
 
 
 
 
 
 
 
 
Figure S8 
Breakdown of the bacteria isolated from sample eight (Ulva lactuca) samples ranging from phylum 
to species. 
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Figure S9 
Breakdown of the bacteria isolated from sample nine (Ulva lactuca) samples ranging from phylum to 
species. 
 
 
 
 
 
 
 
 
 
Figure S10 
Breakdown of the bacteria isolated from sample ten (Furcellaria lumbricalis) samples ranging from 
phylum to species. 
 
 
 
 
 
 
 
 
Figure S11 
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Breakdown of the bacteria isolated from sample eleven (Furcellaria lumbricalis) samples ranging 
from phylum to species. 
 
 
 
 
 
 
 
 
Figure S12 
Breakdown of the bacteria isolated from sample twelve (Furcellaria lumbricalis) samples ranging 
from phylum to species. 
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